
==== Front
Behav Sci (Basel)
Behav Sci (Basel)
behavsci
Behavioral Sciences
2076-328X
MDPI

34209185
10.3390/bs11070097
behavsci-11-00097
Review
Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside
https://orcid.org/0000-0002-5136-9452
Shad Mujeeb U. 123
Echeverria Valentina Academic Editor
1 Spring Valley Hospital and Medical Center, Valley Health System, Las Vegas, NV 89118, USA; mujeebushad@gmail.com
2 Department of Psychiatry, University of Nevada, Las Vegas, NV 89154, USA
3 College of Osteopathic Medicine, Touro University Nevada, Las Vegas, NV 89014, USA
30 6 2021
7 2021
11 7 9713 5 2021
23 6 2021
© 2021 by the author.
2021
https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
There is growing research interest in learning the genetic basis of response and adverse effects with psychotropic medications, including antipsychotic drugs. However, the clinical utility of information from genetic studies is compromised by their controversial results, primarily due to relatively small effect and sample sizes. Clinical, demographic, and environmental differences in patient cohorts further explain the lack of consistent results from these genetic studies. Furthermore, the availability of psychopharmacological expertise in interpreting clinically meaningful results from genetic assays has been a challenge, one that often results in suboptimal use of genetic testing in clinical practice. These limitations explain the difficulties in the translation of psychopharmacological research in pharmacogenetics and pharmacogenomics from bench to bedside to manage increasingly treatment-refractory psychiatric disorders, especially schizophrenia. Although these shortcomings question the utility of genetic testing in the general population, the commercially available genetic assays are being increasingly utilized to optimize the effectiveness of psychotropic medications in the treatment-refractory patient population, including schizophrenia. In this context, patients with treatment-refractory schizophrenia are among of the most vulnerable patients to be exposed to the debilitating adverse effects from often irrational and high-dose antipsychotic polypharmacy without clinically meaningful benefits. The primary objective of this comprehensive review is to analyze and interpret replicated findings from the genetic studies to identify specific genetic biomarkers that could be utilized to enhance antipsychotic efficacy and tolerability in the treatment-refractory schizophrenia population.

genetic testing
antipsychotic
pharmacotherapy
schizophrenia
==== Body
1. Introduction

Genetic testing is increasingly utilized to identify genetic biomarkers for optimizing the efficacy and tolerability of psychotropic drugs, especially antidepressants. However, genetic testing is also being requested to enhance the effectiveness of antipsychotic drugs, which is especially true for the treatment-refractory schizophrenia population, who frequently experience irrational polypharmacy at high dosages with significant adverse effects, generally without much therapeutic benefit. Currently, the most evidence in supporting genetic assays is based on pharmacogenetic (PG) studies, which utilize a candidate gene(s) approach investigating the effect(s) of genetic polymorphism(s) on efficacy, tolerability, and/or safety of antipsychotic drugs [1]. Most clinically meaningful findings have been reported using genetic factors affecting the pharmacokinetics (PKs) of antipsychotic drugs, such as genetic polymorphisms in the drug-metabolizing cytochrome-P450 (CYP) enzymes to identify and/or predict effective and tolerable dosages of an antipsychotic drug. In contrast, findings from PG studies investigating genetic variance in pharmacodynamic (PD) factors, such as transporters, neuropeptides, and receptors, have produced inconsistent results, which is most likely due to the small sample sizes (limiting sub-group analyses) resulting in small effect sizes, lack of control for confounding factors (affecting efficacy and/or tolerability), and medication nonadherence further compromising the results. Despite these limitations, PG studies investigating PD genetic factors may be helpful to enhance the effectiveness of antipsychotic drugs with more success in the treatment-refractory population. Compared to PG studies, pharmacogenomic (PGx) studies require much larger samples to explore all potential associations between the effectiveness of antipsychotic drugs and multiple genes of the molecular targets for the antipsychotic drugs. Although Genome-Wide Association Studies (GWAS) provide the first logical step to explore these associations, these studies can be significantly expensive, which explains their scarcity in psychiatry. The lack of optimal research explains difficulties in the clinical application of genetic findings from the bench to the bedside. This review is a comprehensive analysis of findings from a large number of positive and negative genetic studies to provide insights into specific genetic biomarkers that could be utilized to optimize antipsychotic efficacy and tolerability, especially in the treatment-refractory schizophrenia population. The review also offers a brief discussion of commercially available genetic assays and future research directions to enhance the clinical utility of genetic testing in psychiatry.

2. Pharmacogenetic Studies

The data from PG studies are clinically utilized at the individual level to predict and optimize the response to antipsychotic drugs while preventing or minimizing adverse events. A drug’s response or tolerability can be affected by genetic polymorphisms in PK factors, which determine the concentration of a drug at its site(s) of action, and PD factors, which determine a drug’s response or tolerability at its molecular targets. However, these distinctions are rather arbitrary, as changes in a drug’s concentration at the site of action (i.e., PKs) are always associated with changes in a drug’s efficacy and/or tolerability (i.e., PDs) at its site(s) of action. The following section will review the PK and PD genetic findings from the pharmacogenetic studies, followed by a brief discussion of pharmacogenomic studies, commercially available assays, and future directions.

2.1. Pharmacokinetic (PK) Genetic Biomarkers

Genetic variance in drug-metabolizing enzymes, such as CYP enzymes, represents most of the PK biomarkers. The genetic polymorphisms of CYP enzymes have produced one of the most replicated and clinically relevant findings in patients who develop adverse effects on routinely administered dosages of an antipsychotic drug. A similar statement cannot be made for antipsychotic efficacy, probably because there is no apparent relationship between plasma levels of an antipsychotic drug and antipsychotic response with the exception of clozapine. In this context, CYP2D6 is one of the most clinically relevant enzymes; despite making only 2% of all CYP enzymes in the liver, CYP2D6 is involved in the metabolism of about 25% of several commonly used psychotropic agents, including antipsychotic drugs [2,3]. About 6–10% of Caucasians and 1% of Asians are poor metabolizers [4]. Patients homozygous for wild-type alleles are known as normal or extensive metabolizers, and those homozygous or heterozygous for the dysfunctional allele are labeled as intermediate metabolizers. About 1–2% of Caucasians have multiple copies of functional alleles and are called ultra-rapid metabolizers [5,6]. As compared to extensive metabolizers, patients that are ultra-rapid metabolizers require higher doses and those who are intermediate metabolizers require lower doses of drugs that are substrates for this enzyme due to altered elimination. If antipsychotic doses are not corrected for this genetic variance, ultra-rapid metabolizers for CYP2D6 may experience decrease or loss in efficacy and poor metabolizers may develop higher levels of antipsychotic drugs resulting in adverse effects, such as extrapyramidal symptoms (EPS) and hyperprolactinemia [2]. Despite relatively small sample PG studies, multiple studies have shown a relationship between dysfunctional CYP2D6 variants and antipsychotic-induced EPS, especially tardive dyskinesia (TD) [7,8,9,10,11,12,13,14,15,16,17,18,19,20,21] (Table 1). However, these findings have not been supported in some ethnic groups, such as in Indian [22], Slovenian [23], and Japanese [24] populations. These differences may be explained by small sample sizes and a lower frequency of poor metabolizer alleles for CYP2D6 alleles in these ethnic groups as compared to Caucasians. Nevertheless, a meta-analysis revealed at least one dysfunctional CYP2D6 allele associated with TD and parkinsonian symptoms in patients with schizophrenia [25]. Interestingly, most of these PG studies reporting an association between antipsychotic drugs and EPS failed to show a significant correlation between CYP2D6 variants and the efficacy of antipsychotic drugs [3]. However, many studies have been small, and many have not been adequately powered to capture more subtle changes in efficacy compared to more clinically visible EPS.

Deficient activity of CYP enzyme 1A2 has also been associated with adverse effects due to an increase in plasma levels of antipsychotic drugs that are substrates for this enzyme, such as clozapine and olanzapine [21,42,43]. In contrast, patients with high inducibility of CYP1A2, as observed with smoking in some patients, may end up with subtherapeutic levels of clozapine and olanzapine [44]. One study associated genetic variance in CYP3A4 activity with the efficacy of risperidone, an antipsychotic drug [45], while other studies produced negative results [19,22]. However, polymorphism in a specific transporter, P-glycoprotein (also known as multiple drug resistance-1 (MDR1) or ATP-binding cassette subfamily B member1 gene [46]) has been correlated with efficacy as well as tolerability of risperidone [47] and clozapine [48].

2.2. Pharmacodynamic (PD) Biomarkers

2.2.1. Antipsychotic Response

Antipsychotic efficacy across different antipsychotic drugs has been strongly linked with genetic variance in dopamine-2 receptors (DRD2). More specifically, D2−141C Del and TaqI A2 allelic variants have been associated with the inadequate antipsychotic response across various ethnic groups [49,50,51,52]. A comprehensive metanalysis supported the relationship between D2−141C Del and TaqI A2 allelic variants and antipsychotic response [26] (Table 1). Polymorphisms of the promotor regions of DRD2, DRD3, and DRD4 have also been linked with antipsychotic efficacy [52,53,54,55,56]. Another biomarker repeatedly associated with antipsychotic efficacy is catechol-o-methyl transferase (COMT), which primarily metabolizes dopamine [57,58,59,60] (Table 1). This finding was also supported by a meta-analysis [32], which showed that patients with met/met homozygosity were more likely to respond to antipsychotic drugs, especially the newer ones.

Specific polymorphisms in serotonin receptors have also been linked with the antipsychotic response, especially serotonin-2A receptors (HRT2A) 102-C/C genotype, which was associated with reduced antipsychotic efficacy in Caucasian patients [61,62] (Table 1). Another HTR2A genotype, 1438-A/A, has been correlated with antipsychotic response in various ethnic groups. Lack of antipsychotic efficacy and treatment resistance for negative symptoms were found in a French cohort with 5-HT2A −1438-A/A genotype [63]. In Algerian patients, 5-HT2A −1438-G allele was associated with psychotic relapse [64]. Another polymorphism in serotonin receptor, HTR1A (i.e., 5-HT1A −1019G), has been associated with lower antipsychotic efficacy in various ethnic groups [28,29,30]. The association between symptom reduction and guanine nucleotide-binding protein subunit beta-3 variant was reported in more than one study [65,66]. However, the correlation between the L allele of 5-HTT LPR (serotonin transporter-linked promoter region) and improvement in negative symptoms of schizophrenia was observed in one study [67], while two other studies were negative [68,69]. Although multiple other reports have also observed association between specific PD markers and antipsychotic efficacy, these findings are without replication and questionable clinical utility [70,71,72,73,74,75,76,77,78,79].

Some studies have examined the pharmacogenetics of commonly used antipsychotic drugs, such as clozapine, risperidone, and olanzapine. In this context, clozapine, which is still the gold standard in the management of treatment-refractory schizophrenia, is the most extensively studied antipsychotic drug. Several studies have examined dopamine receptor polymorphisms to explain clozapine’s unique efficacy and have found replicated genetic variance in DRD1 [80,81], DRD2 [82,83], DRD3 [84,85], and DRD4 [86,87] to be associated with clozapine efficacy. However, results with DRD3 were not supported by a recent meta-analysis [88], while the findings with DRD4 were not replicated in other studies [89,90]. Association between clozapine’s efficacy and genetic variance in the dopamine transporter protein (DAT) has been supported by one study [91] but not the other [55]. However, one of the most robust findings with clozapine has been the correlation between HTR2A polymorphisms and clozapine treatment outcomes [62,92,93,94,95]. The results with HTR2A variants 102-T/C and Tyr452 were also confirmed by a meta-analysis [31] (Table 1). A comprehensive review documented correlations between antipsychotic efficacy and lower expression of HTR2A variants 102-C and -1438-G, and decreased functioning of HTR2A variant Tyr452 [1]. Other serotonin mechanisms have also been linked with clozapine’s efficacy, such as variance in serotonin-2C (HTR2C) receptors [96,97] and SLC6A4 (solute carrier family 6 member 4 serotonin transporter) [67,98]. A combinatorial genetic assay for three HTR2A variants (i.e., 452Tyr, 1438–G/A, and 102–T/C), two HTR2C variants (i.e., 330–GT/244–CT and Cys23Ser), and one SLC6A4 variant provides the best predictive model for clozapine response with 76.7% positive predictive value and 95% sensitivity [97,98]. Despite several studies producing negative results with polymorphisms in various serotonin targets [67,99,100,101,102,103,104,105,106,107], the overall data support the critical role of the serotonin system in clozapine’s efficacy. However, clozapine response has not been associated with genetic variance in other important clozapine-targeted receptors, such as adrenergic and glutamatergic receptors [108,109,110].

Risperidone is another second-generation antipsychotic drug, which has shown decreased antipsychotic efficacy in patients with DRD2 Ser311 [111] variant associated with the reduced response at DRD2 receptors [112]. On the other hand, the D2-241-A allele was associated with a greater antipsychotic response with risperidone than the −241-G allele in two studies [113,114]. A catechol-o-methyl transferase (COMT) variant (i.e., Val 158Met) has also been associated with lower risperidone efficacy in two studies [115,116] and a metanalysis [32] (Table 1) as has been associated with a serotonin receptor variant, HRT2A 102-C, in Chinese [117], Korean [118], and Japanese [119] patients, but not in Caucasians [1]. Nevertheless, this relationship between COMT variant and antipsychotic efficacy points towards the importance of dopamine levels in antipsychotic response. Risperidone efficacy has also been linked with variance in brain-derived neurotrophic factor (BDNF) in two studies [120,121]. However, unlike clozapine, no correlation was reported between risperidone response and DRD4 variance [122]. Other genetic findings with risperidone have been in single studies and will not be reviewed here [28,53,113,119,123,124,125,126,127,128,129]. The findings from these single studies need to be replicated to be clinically relevant.

Olanzapine is another commonly used second-generation antipsychotic drug with reports of an association between its efficacy and DRD3 variant D3Ser9Gly [130,131], which has also been associated with antipsychotic efficacy of risperidone and clozapine [130,131]. However, this finding was not replicated in Indian patients [132], suggesting ethnic differences in response. Unlike risperidone, genetic variance in COMT was associated with olanzapine’s efficacy in only one study [133]. In terms of serotonergic mechanisms, none of the findings with variance in the L allele of the 5-HTT LPR [134] and HTR6 polymorphisms [135] associated with olanzapine’s efficacy have been replicated. However, once again, this olanzapine response was not associated with HRT2A and HRT2C variants in the Indian population [131,132], highlighting the ethnic differences in antipsychotic response. Glutamate metabotropic receptor-3 polymorphism [136] associated with better olanzapine response in only one study, a positive olanzapine’s response with calcium channel variant, calcium voltage-gated channel subunit alpha1 C, rs1006737 was replicated in two studies [137,138].

Although aripiprazole is classified as one of the newer second-generation antipsychotic drugs, it is the first antipsychotic drug with partial agonist activity at D2 receptors and 5HT1A receptors [139]. A couple of studies have documented an association between D2 TaqI variants and the efficacy of aripiprazole in Korean and Chinese patients [140,141]. In summary, there is inadequate genetic data to compare clinically meaningful differences in genetically mediated antipsychotic response between different antipsychotic drugs, perhaps with the exception of clozapine.

2.2.2. Antipsychotic Adverse Effects

The genetic data for antipsychotic tolerability is not as consistent as those for antipsychotic efficacy, except for weight gain. The margin for controversial results is much higher than those from the efficacy studies, as documented below.

Extrapyramidal Symptoms (EPS)

Although genetic polymorphisms in CYP enzymes are grouped under PK biomarkers, it is worth mentioning here that any change in a drug’s metabolism will eventually be expressed pharmacodynamically. Thus, the poor metabolizers for CYP2D6 have a higher risk for developing EPS due to increased plasma levels of antipsychotic drugs that are CYP2D6 substrates [7,8,9,10,11,12,13,14,15,16,17,18,19,20,21] (Table 1). However, the relationship between D2Rs polymorphisms and the development of EPS remains unclear [40]. Although some studies have found a correlation between DRD2 variants and EPS [142,143,144,145], many others have not [19,146,147,148,149,150,151,152,153,154,155]. Nevertheless, a metanalysis did report a significant correlation between DRD2 polymorphism (i.e., TAq1A) and TD [40] (Table 1). The results examining relationship between EPS and DRD3 polymorphisms are also controversial; some studies supported the relationship [19,147,150,156,157,158,159,160,161,162,163], but some did not [143,147,150,164,165,166,167], while some strangely reported paradoxical results [168,169,170]. One study found an interaction between DRD3 and CYP 17A1 genotypes and EPS [158]. Another study reported no correlation between variance in DRD1 and EPS [155]. A couple of studies found a direct association between two variants of dopamine metabolizing enzyme, COMT (G158A and A-278G) and risk for TD [148,171]. However, results were negative with another COMT variant, Val158Met [146,172,173,174]. No associations were reported with genetic variance in other dopamine targets, such as dopamine transporter-1 (DAT1) [146,147,175] and polymorphisms of dopamine-related enzymes, monoamine oxidase A, and monoamine oxidase B [146,174]. The relationship between the regulator of the G-protein signaling 2 gene and pseudo-parkinsonian symptoms was supported in Caucasian [176,177] as well as in Japanese [178] patients.

Genetic variance in the serotonergic system has also produced inconsistent results; some reports have documented associations between HRT2A polymorphisms and TD [150,170,179,180], and some have not [143,172,181,182]. However, pooled data from 635 patients reported a correlation between the HRT2A 102-C allele and age-related increase in risk for TD [39] (Table 1). A link between TD and HRT2C variant Cys23Ser was supported by several studies [143,163,183,184,185], but not all [109,143,163,181]. In addition, no relationship was discovered between EPS and HRT2A or serotonin transporter (SLC6A4) gene variants [172,186,187]. Although three studies linked polymorphism in the brain-derived neurotrophic factor (BDNF) gene with the risk of TD [120,165,188], one study produced negative results [168]. Polymorphism in a p-glycoprotein transporter gene, ATP-binding cassette sub-family B member 1 (ABCB1), was only marginally associated with dystonia and akathisia [189]. No clear associations were observed between EPS and genes involved in oxidation and stress, such as manganese superoxide dismutase [190,191,192], nitric oxide synthase [193,194,195], glutathione S-transferase [196], and glutathione peroxidase [197]. Only marginal associations were reported with polymorphism in nicotinamide adenine dinucleotide phosphate (NADPH), dehydrogenase quinone, nitric oxide synthase 3 [198,199], and glutathione S-transferase μ1 [19]. Polymorphisms in angiotensin I converting enzyme [156] and protein kinase B [200] were not found to correlate with EPS as well. However, in one study, EPS were associated with polymorphism in adrenergic type 1A receptors [201]. Despite inconsistent results from reviewed studies, the overall data do support an important role for dopamine and serotonin systems in the development of antipsychotic drugs-induced EPS.

Hyperprolactinemia

Although there is not much research investigating the role of genetic variance on antipsychotic-induced hyperprolactinemia, any DRD2 polymorphism that increases the risk for EPS will also increase the risk for hyperprolactinemia, as both adverse effects are mediated by D2R blockade. In this context, one study did report 40% higher prolactin levels in patients with DRD2*A1 allele than those without [202]. Interestingly, this increase in prolactin was also observed with clozapine, which is least likely to increase prolactin levels [202].

Weight Gain and Metabolic Syndrome

Serotonin is one of the main neurotransmitter systems that control feeding behavior in the hypothalamus and is targeted by the second-generation antipsychotic drugs via their blocking effects on 5HT2C receptors [203]. Although the genetic mechanisms underlying weight gain due to HTR2C polymorphisms are not completely clear, several HRT2C gene haplotypes have been associated with weight gain and metabolic syndrome [34,35,36,37]. Haplotype A (-997G, -759C, -697G) was the most robustly associated haplotype with antipsychotic-induced weight gain. In contrast, presence of haplotype B (-997A, -759T, -697C) was found to be protective against antipsychotic-induced weight gain [204,205,206,207,208,209,210] (Table 1). One of these haplotypes, B (i.e., -759T), has been associated with decreased expression of 5HT2C receptors [33]. Increased negative feedback due to increased levels of leptin observed in patients with haplotype B may explain the resistance against weight gain [27]. Interestingly this weight resistance with haplotype B was not observed in younger patients [211]. Although a meta-analysis revealed a 100% increase in risk for weight gain in patients with HRT2C -759 C allele [212], there were studies that did not find any correlation between the presence of the -759 C allele and weight gain [213,214,215,216,217]. In addition, no relationship was observed between weight gain and another HRT2C polymorphism, Cys23Ser [212,218,219]. Genetic variance in other serotonin receptors, such as HRT2A 102-T/C, have also been associated with weight gain, obesity, and lipid levels [34,220,221], except one study [219]. No association was documented with a HRT1A polymorphism [220]. Finally, a short allele of the serotonin transporter gene (i.e., 5-HTT LPR) was significantly associated with weight gain and obesity in the Caucasian population [134,221], but not in Chinese patients [219].

Although earlier studies did find an association between weight gain and genetic variance in DRD2 [220,222] or DRD3 [220], one recent study did observe a positive relationship between weight gain and DRD2 variants rs6277 (C957T), rs1079598, and rs1800497 (TaqIA) [223]. In addition, a functional promoter region variant in DRD2 was implicated in a study of antipsychotic drug-induced weight gain during early psychosis with minimal prior exposure to antipsychotic drugs [224]. Carriers of –141C Ins/Del in the DRD2 promoter gene demonstrated substantially more weight gain than noncarriers after 6 weeks of treatment with risperidone or olanzapine. Another study reported an association between an increase in body mass index and a DRD4 variable number tandem repeat allele during antipsychotic treatment [218].

Few studies have reported a significant correlation between genetic polymorphism in melanocortin 4 receptors (MC4R) and antipsychotic-induced weight gain [225,226], which is also supported by a genome-wide association study [38] (Table 1). Several studies have reported involvement of the adrenergic receptor 2A in treatment-related weight gain, although with differential effects across various ethnic groups [227,228,229]. Genetic variance in other adrenergic receptors, such as 5HT1A, have also been associated with changes in body mass index [230]. Leptin appears to play an important role in mediating antipsychotic drug-induced weight gain, as reflected by the association between a leptin gene variant, −2548-A/G, and weight gain, despite the different direction of these results [209,216,231,232,233]. Results with leptin studies were also inconclusive across various ethnic groups, such as Indians [171] and Germans [37]. Interestingly, this leptin variant was not associated with weight gain in patients with premorbid obesity [234]. One study also found a correlation between a leptin receptor polymorphism and weight gain [234].

One study reported a correlation between antipsychotic-induced weight gain and polymorphism in insulin-induced gene 2 [235], but a couple of other studies did not [37,236]. Similarly, the association between guanine nucleotide-binding protein subunit beta-3 polymorphism and weight gain in Indians [132] was not replicated in other ethnic groups, such as Koreans [237], Taiwanese [238], and Caucasians [239]. One study failed to find any association between the histamine-1 receptor gene and antipsychotic-induced weight gain [240]. Results were also negative with the cholecystokinin gene [241]. However, associations have been reported between weight gain and/or metabolic syndrome and apolipoprotein E [242], brain-derived neurotrophic factor [220,243], cannabinoid receptor-1 [244], CYP2D6 [220,245], multidrug resistance 1 [217], methylenetetrahydrofolate reductase [246,247], peroxisome proliferator-activated receptor-γ [248], synaptosomal-associated protein 25 [249], and tumor necrosis factor [250,251].

Agranulocytosis

Agranulocytosis is a rare but severe and potentially lethal adverse effect associated with clozapine use. Pharmacogenetic studies have reported strong associations between polymorphisms in the major histocompatibility complex and clozapine-induced agranulocytosis [252,253,254]. Two cohorts from a clozapine study found significantly high odds ratios (16.9) for agranulocytosis in patients with a human leukocyte antigen (HLA)-DQB1, which is a single-nucleotide polymorphism (i.e., 6672G > C) with high specificity and sensitivity rates [41] (Table 1). Another study proposed that the patients with a history of clozapine-induced granulocytopenia but without the variant HLA-B*59:01 may be successfully re-challenged with clozapine [255]. However, similar to results from the genetic studies investigating antipsychotic-induced TD, involvement of oxidative genes in bone marrow toxicity has also produced inconsistent results, as reflected by a marginal association with NADPH quinone 2 (NQO2) polymorphism [256] and negative results with myeloperoxidase [257,258]. An association with clozapine-induced agranulocytosis was also reported with tumor necrosis factor [259] but not with cytochrome b-245 α polypeptide [257] or with CYPD26 [258] variants.

3. Pharmacogenomic (PGx) Studies

These studies have primarily explored the effects of genetically mediated PD differences in a drug’s response and/or adverse effects through a systematic assessment of genes, their products, and individual variation in gene expression and function. In this context, GWAS are most useful to generate hypotheses that can be later confirmed in future studies. These studies explore associations between multiple genes and psychotropic drugs [260]; therefore, they require large cohorts associated with high costs, which explains the scarcity of these studies with psychotropic medications. This may be the reason why most GWAS studies with antipsychotic drugs are primarily based on post hoc analyses from a large effectiveness trial, CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) [261,262,263,264,265]. Polymorphisms in the ankyrin repeat and sterile α motif domain containing 1B (ANKS1B) and contactin-associated protein-like 5 were linked to the efficacy of olanzapine and risperidone in terms of negative symptoms [265]. In addition, earlier GWAS identified genes from a region in chromosome 12 that were associated with antipsychotic-induced weight gain [266], GABAergic genes related to drug-induced TD [267], and HLA B*59:01 correlated with clozapine-induced agranulocytosis [255]. Another GWAS found 20 statistically significant polymorphisms at a single locus near the melanocortin 4 receptor (MC4R) gene associated with weight gain in patients undergoing the first trial with antipsychotic drugs, which is consistent with a region previously identified by large-scale GWAS of obesity in the general population [38]. These data implicate MC4R in extreme SGA-induced weight gain and related metabolic disturbances. Most recently, polygenic risk scores derived from significantly associated SNPs with schizophrenia patients of European ancestry were found to inversely correlate with the antipsychotic response [268]. It will be interesting to see if these results become more significant in specific sub-group analyses, such as males versus females, age at onset, and European versus non-European samples [268].

Antipsychotic treatment in a subset of 738 schizophrenia patients from the CATIE study [264] polymorphisms localized within or close to the genes, ETS homologous factor, solute carrier family 26 member 9 (SLC26A9), DRD2, G protein-coupled receptor 137B, carbohydrate sulfotransferase 8, and interleukin1-alpha (IL1A) was associated with improvements in various neurocognitive domain areas. A significant result was also found for the variant rs286913 in the ETS homologous factor related to the effects of ziprasidone on vigilance. Furthermore, the presence of rs11240594 in the SLC26A9 gene and rs11677416 in the IL1A gene was linked to olanzapine-induced improvement in processing speed and working memory.

4. Commercially Available Genetic Assays

These assays offer genetic testing for multiple genetic biomarkers (combinatorial assays) for treatment response and/or tolerability identified in other studies to facilitate the selection of effective psychotropic medications. The clinical utility of these combinatorial genetic assays has primarily been tested in underpowered and open-label studies. Thus, these assays with specific panels for different groups of psychotropic drugs are based on findings from other studies using a candidate gene(s) approach. Although there is no specific genetic assay for antipsychotic drugs, combinatorial genotyping of genetic biomarkers is used to optimize the efficacy and tolerability of antipsychotic drugs, especially in the treatment-refractory population. In this context, genetic variance in PK biomarkers (primarily the CYP enzyme system) has been clinically helpful to optimize antipsychotic treatment. Most genetically relevant CYP enzyme assays for antipsychotic drugs include CYP1A2, CYP2D6, and CYP2C19. AmpliChip™ is the only FDA-approved genetic test, which is a microarray-based product to assess the activity of CYP2D6 and CYP2C19 and can be helpful in a large number of psychiatric patients as multiple psychotropic drugs are metabolized by these two CYP enzymes. Genetic testing for CYP2D6 is among the most clinically relevant investigation, as several important psychotropic drugs, including antipsychotic drugs, such as haloperidol, perphenazine, and risperidone, are metabolized by this enzyme. Following are the major resources and genetic assay companies that offer genetic testing for psychotropic drugs.

The GeneSight® (Myriad Health®, South San Francisco, CA, USA) combinatorial assays provide coverage for about 50 PK alleles, including those for CYP2D6, CYP2C19, CYP2C9, CYP2B6, CYP3A4, and CYP1A2, and some PD genes (5HTT, HTR2A, COMT, CACNA1C, MTHFR). On the basis of information on these genetic biomarkers, an individualized report is created which divides psychotropic medications into a green bin for recommended use, a yellow bin for use with caution, and a red bin use with extreme caution and frequent monitoring.

GeneceptTM assay (Genomind®) also provides testing for PK biomarkers (CYP2D6, CYP2C19, CYP3A4) and PD markers, (5HT transporter, 5HT2C receptors, DRD2, COMT, CACNA1C, ANK3, and MTHFR). Like the GeneSight report, each patient’s results are provided to the ordering clinician, along with suggested therapeutic options.

Drug-Metabolizing Enzymes and Transporters (DMET™) Plus Solution is one of the largest commercially available genetic assays for about 2000 PK variants across multiple genes. The DMET™Plus Solution was developed as a platform to identify genetic variance and has not been tested for its efficacy in enhancing clinical outcomes with psychotropic drugs.

5. Future Directions

One of the most important goals for future genetic research in psychopharmacology will be to replicate and validate results from small sample genetic studies to resolve inconsistent results. However, these goals can only be accomplished by large, prospective, well-conducted multisite clinical trials such as genome-wide association studies to allow subgroup analyses and provide control for demographic, clinical, and environmental factors while close monitoring for medication adherence. In this context, the clinical trial network model used in oncology and cardiology has already been initiated in psychiatry, including Implementing Genomics in Practice (IGNITE), the Dutch Pharmacogenetics Working Group, and the Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment. These large-scale initiatives will offer an effective tool to explore the relationship between efficacy and tolerability of various antipsychotic drugs and multiple genetic variants to generate hypotheses that could be tested in hypothesis-driven randomized controlled trials to improve and expand on currently available genetic biomarkers. A minimum set of genes and alleles is required for consistent pharmacogenomic decision-making before combinatorial genetic assays can be used beyond the treatment-refractory population. With the growing research in this area, it is only a matter of time that these efforts will help develop comprehensive combinatorial commercially available assays and toolkits with clinical utility beyond the treatment-refractory patient population facilitating the application of bench research to the clinical bedside. Equally importantly, clinicians must be trained and updated to enhance clinical application and interpretation of results from the existing and ongoing genetic studies with psychotropic medications, including antipsychotic drugs.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

Supplemental list for acronyms and abbreviations in alphabetical order 5-HTT LPR	serotonin-transporter-linked promoter region	
CATIE	Clinical Antipsychotic Trials of Intervention Effectiveness	
COMT	catechol-o-methyl transferase	
CYP	cytochrome-P450	
DAT	dopamine transporter	
DRD1	dopamine-1 receptors	
DRD2	dopamine-2 receptors	
DRD3	dopamine-3 receptors	
DRD4	dopamine-4 receptors	
EHF	ETS homologous factor, solute carrier family 26 member 9 (SLC26A9)	
EPS	extrapyramidal symptoms	
GWAS	genome-wide association studies	
HLA	human leukocyte antigen	
HTR2A	serotonin-2A receptors	
HTR2C	serotonin-2A receptors	
IGNITE	Implementing Genomics in Practice	
IL1A	interleukin1-alpha	
MC4R	melanocortin 4 receptor	
MDR1	multiple drug resistance-1	
NADPH	nicotinamide adenine dinucleotide phosphate	
PD	pharmacodynamic	
PG	pharmacogenetic	
PGx	pharmacogenomic	
PK	pharmacokinetic	
SLC26A9	solute carrier family 26 member 9	
SLC6A4	solute carrier family 6 member 4—serotonin transporter gene	
SNP	single nucleotide polymorphism	
TD	tardive dyskinesia	

behavsci-11-00097-t001_Table 1 Table 1 Genetic biomarkers for antipsychotic response and adverse effects.

Antipsychotic Response	
Gene	Polymorphism	Risk Allele	Functional Outcome	Clinical Outcome	Statistical Significance	
DRD2	-141C Ins/Del (rs1799732)	Del	Decreased DRD2 expression	Lower antipsychotic response	Odds ratio = 0.65
95% confidence interval = 95% CI: 0.43–0.97 [26]	
HTR1A	C-1019G	G	Increased HTR1A expression	G/G homozygosity with lesser negative symptom improvement [27,28,29,30]	p = 0.003	
HTR2A	T-102-C (rs6313)	C	Decreased HTR2A expression	C/C homozygosity with lower antipsychotic response	Odds ratio = 0.61
95% confidence interval = 0.43–8.5 [31]	
COMT	Val 158Met	Val	Faster metabolism resulting in lower levels of dopamine	Lower antipsychotic response [32]	Odds ratio = 1.37;
95% confidence interval = 1.02–1.85)	
Weight Gain	
HTR2C	C-759T (rs3813929)	C	Lesser expression of HTR2C receptors [33]	>7% weight gain over baseline with C allele	Odds ratio = 1.64;
95% confidence interval = 0.73–3.69 in chronic subjects [34,35,36,37];
Odds ratio = 5.40
95% confidence interval = 2.08–14.01 during early psychosis [34,35,36,37].	
MC4R	Rs489693	A	Unknown	AA homozygotes gained about 3 kg more weight than other genotypes [38]	Odds Ratio (95% confidence interval)	
Tardive Dyskinesia	
CYP2D6	Presence of at least one dysfunctional alleles	One of
3, 4, 5, 6, or 10 alleles	Decreased CYP2D6 enzyme activity	Increased risk for tardive dyskinesia	1.83 95% CI: 1.09–3.08) [7,8,9,10,11,12,13,14,15,16,17,18,19,20,21]	
HTR2A	T102C	C	Decreased HTR2A expression and binding	Presence of tardive dyskinesia	1.64 95% CI: 1.17–2.32 [39]	
DRD2	Taq1A (rs1800497)	C, A2	Increased DRD2 receptors and binding	Presence of tardive dyskinesia	1.30 95% CI: 1.09–1.55 [40]	
Agranulocytosis	
HLADQB1	G6672C
(rs1133322494)	G	? autoimmune effect	Clozapine discontinuation due to ANC < 500 cells/mm3	Odds ratio = 16.9 [41]	

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Arranz M.J. de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: A review of last decade of research Mol. Psychiatry 2007 12 707 747 10.1038/sj.mp.4002009 17549063
2. Crescenti A. Mas S. Gasso P. Parellada E. Bernardo M. Lafuente A. Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy Clin. Exp. Pharmacol. Physiol. 2008 35 807 811 10.1111/j.1440-1681.2008.04918.x 18346175
3. Ravyn D. Ravyn V. Lowney R. Nasrallah H.A. CYP450 pharmacogenetic treatment strategies for antipsychotics: A review of the evidence Schizophr. Res. 2013 149 1 14 10.1016/j.schres.2013.06.035 23870808
4. Cai W.M. Chen B. Zhang W.X. Frequency of CYP2D6*10 and *14 alleles and their influence on the metabolic activity of CYP2D6 in a healthy Chinese population Clin. Pharmacol Ther. 2007 81 95 98 10.1038/sj.clpt.6100015 17186005
5. Demirtas D. Sumbul H.E. Bulut A. Demirtas A.O. Gulumsek E. Koca H. Icen Y.K. Koc M. Tp-e interval, Tp-e/QT and Tp-e/QTc ratio in hypertensive patients with primary aldosteronism Clin. Exp. Hypertens. 2020 42 93 98 10.1080/10641963.2019.1632341 31204516
6. Gasche Y. Daali Y. Fathi M. Chiappe A. Cottini S. Dayer P. Desmeules J. Codeine intoxication associated with ultrarapid CYP2D6 metabolism N. Engl. J. Med. 2004 351 2827 2831 10.1056/NEJMoa041888 15625333
7. Arthur H. Dahl M.L. Siwers B. Sjoqvist F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia J. Clin. Psychopharmacol. 1995 15 211 216 10.1097/00004714-199506000-00010 7635999
8. Andreassen O.A. MacEwan T. Gulbrandsen A.K. McCreadie R.G. Steen V.M. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients Psychopharmacology 1997 131 174 179 10.1007/s002130050281 9201806
9. Armstrong M. Daly A.K. Blennerhassett R. Ferrier N. Idle J.R. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype Br. J. Psychiatry 1997 1702 3 26 10.1192/bjp.170.1.23 9068770
10. Kapitany T. Meszaros K. Lenzinger E. Schindler S.D. Barnas C. Fuchs K. Sieghart W. Aschauer H.N. Kasper S. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia Schizophr. Res. 1998 32 101 106 10.1016/S0920-9964(98)00038-3 9713905
11. Scordo M.G. Spina E. Romeo P. Dahl M.L. Bertilsson L. Johansson I. Sjoqvist F. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients Eur. J. Clin. Pharmacol. 2000 56 679 683 10.1007/s002280000222 11214775
12. Lam L.C. Garcia-Barcelo M.M. Ungvari G.S. Tang W.K. Lam V.K. Kwong S.L. Lau B.S. Kwong P.P. Waye M.M. Chiu H.F. Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients Pharmacopsychiatry 2001 34 238 241 10.1055/s-2001-18035 11778144
13. Ellingrod V.L. Schultz S.K. Arndt S. Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6 Pharmacotherahy 2002 22 1416 1419 10.1592/phco.22.16.1416.33700 12432967
14. Jaanson P. Marandi T. Kiivet R.A. Vasar V. Vaan S. Svensson J.O. Dahl M.L. Maintenance therapy with zuclopenthixol decanoate: Associations between plasma concentrations, neurological side effects and CYP2D6 genotype Psychopharmacology 2002 162 67 73 10.1007/s00213-002-1059-5 12107620
15. Nikoloff D. Shim J.C. Fairchild M. Patten N. Fijal B.A. Koch W.H. MacPherson A. Flockhart D. Yoon Y.R. Yoon J.S. Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics Pharm. J. 2020 2 400 407 10.1038/sj.tpj.6500138 12629505
16. Inada T. Senoo H. Iijima Y. Yamauchi T. Yagi G. Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients Psychiatr. Genet. 2003 13 163 168 10.1097/00041444-200309000-00005 12960748
17. Lohmann P.L. Bagli M. Krauss H. Müller D.J. Schulze T.G. Fangerau H. Ludwig M. Barkow K. Held T. Heun R. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients Pharmacopsychiatry 2003 36 73 78 10.1055/s-2003-39048 12734765
18. Liou Y.J. Wang Y.C. Bai Y.M. Lin C.C. Yu S.C. Liao D.L. Lin M.W. Chen J.Y. Lai I.C. Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients Neuropsychobiology 2004 49 167 173 10.1159/000077360 15118351
19. de Leon J. Susce M.T. Pan R.M. Koch W.H. Wedlund P.J. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness J. Clin. Psychopharmacol. 2005 25 448 456 10.1097/01.jcp.0000177546.34799.af 16160620
20. Patsopoulos N.A. Ntzani E.E. Zintzaras E. Ioannidis J.P. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: A meta-analysis Pharmacogenet. Genom. 2005 15 151 158 10.1097/01213011-200503000-00003
21. Fu Y. Fan C.H. Deng H.H. Hu S.H. Lv D.P. Li L.H. Wang J.J. Lu X.Q. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients Acta Pharmacol. Sin. 2006 27 328 332 10.1111/j.1745-7254.2006.00279.x 16490169
22. Tiwari A.K. Deshpande S.N. Rao A.R. Bhatia T. Lerer B. Nimgaonkar V.L. Thelma B.K. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms Schizophr. Res. 2005 75 21 26 10.1016/j.schres.2004.12.011 15820320
23. Plesnicar B.K. Zalar B. Breskvar K. Dolzan V. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment J. Psychopharmacol. 2006 20 829 833 10.1177/0269881106062894 16478753
24. Kakihara S. Yoshimura R. Shinkai K. Matsumoto C. Goto M. Kaji K. Yamada Y. Ueda N. Ohmori O. Nakamura J. Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6 Int. Clin. Psychopharmacol. 2005 20 71 78 10.1097/00004850-200503000-00002 15729081
25. Fleeman N. Dundar Y. Dickson R. Jorgensen A. Pushpakom S. McLeod C. Pirmohamed M. Walley T. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: Systematic review and meta-analyses Pharm. J. 2011 11 1 14 10.1038/tpj.2010.73
26. Zhang J.P. Lencz T. Malhotra A.K. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: A meta-analysis Am. J. Psychiatry 2010 167 763 772 10.1176/appi.ajp.2009.09040598 20194480
27. Reynolds G.P. Hill M.J. Kirk S.L. The 5-HT2C receptor and antipsychoticinduced weight gain-mechanisms and genetics J. Psychopharmacol. 2006 20 15 18 10.1177/1359786806066040 16785265
28. Wang L. Fang C. Zhang A. Du J. Yu L. Ma J. Feng G. Xing Q. He L. The --1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients J. Psychopharmacol. 2008 22 904 909 10.1177/0269881107081522 18308786
29. Reynolds G.P. Arranz B. Templeman L.A. Fertuzinhos S. San L. Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients Am. J. Psychiatry 2006 163 1826 1829 10.1176/ajp.2006.163.10.1826 17012696
30. Mössner R. Schuhmacher A. Kühn K.U. Cvetanovska G. Rujescu D. Zill P. Quednow B.B. Rietschel M. Wölwer W. Gaebel W. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia Pharm. Genom. 2009 19 91 94 10.1097/FPC.0b013e328311a917
31. Arranz M.J. Munro J. Sham P. Kirov G. Murray R.M. Collier D.A. Kerwin R.W. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response Schizophr. Res. 1998 32 93 99 10.1016/S0920-9964(98)00032-2 9713904
32. Huang E. Zai C.C. Lisoway A. Maciukiewicz M. Felsky D. Tiwari A.K. Bishop J.R. Ikeda M. Molero P. Ortuno F. Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: A Meta-Analysis Int. J. Neuropsychopharmacol. 2016 19 pyv132 10.1093/ijnp/pyv132 26745992
33. Buckland P.R. Hoogendoorn B. Guy C.A. Smith S.K. Coleman S.L. O’Donovan M.C. Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain Am. J. Psychiatry 2005 162 613 615 10.1176/appi.ajp.162.3.613 15741483
34. Gunes A. Melkersson K.I. Scordo M.G. Dahl M.L. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine J. Clin. Psychopharmacol. 2009 29 65 68 10.1097/JCP.0b013e31819302c3 19142110
35. Mulder H. Franke B. van der-Beek A.A. Arends J. Wilmink F.W. Scheffer H. Egberts A.C. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia J. Clin. Psychopharmacol. 2007 27 338 343 10.1097/JCP.0b013e3180a76dc0 17632216
36. Mulder H. Cohen D. Scheffer H. Gispen-de Wied C. Arends J. Wilmink F.W. Franke B. Egberts A.C. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: A replication study J. Clin. Psychopharmacol. 2009 29 16 20 10.1097/JCP.0b013e3181934462 19142101
37. Opgen-Rhein C. Brandl E.J. Muller D.J. Neuhaus A.H. Tiwari A.K. Sander T. Dettling M. Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample Pharmacogenomics 2010 11 773 780 10.2217/pgs.10.50 20504252
38. Malhotra A.K. Correll C.U. Chowdhury N.I. Müller D.J. Gregersen P.K. Lee A.T. Tiwari A.K. Kane J.M. Fleischhacker W.W. Kahn R.S. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain Arch. Gen. Psychiatry 2012 69 904 912 10.1001/archgenpsychiatry.2012.191 22566560
39. Lerer B. Segman R.H. Tan E.C. Basile V.S. Cavallaro R. Aschauer H.N. Strous R. Chong S.A. Heresco-Levy U. Verga M. Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype Int. J. Neuropsychopharmacol. 2005 8 411 425 10.1017/S1461145705005389 15857569
40. Zai C.C. De Luca V. Hwang R.W. Voineskos A. Muller D.J. Remington G. Kennedy J.L. Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients Mol. Psychiatry 2007 12 794 795 10.1038/sj.mp.4002023 17767146
41. Athanasiou M.C. Dettling M. Cascorbi I. Mosyagin I. Salisbury B.A. Pierz K.A. Zou W. Whalen H. Malhotra A.K. Lencz T. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis J. Clin. Psychiatry 2011 72 458 463 10.4088/JCP.09m05527yel 20868635
42. Basile V.S. Ozdemir V. Masellis M. Walker M.L. Meltzer H.Y. Lieberman J.A. Potkin S.G. Alva G. Kalow W. Macciardi F.M. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: Association with tardive dyskinesia in schizophrenia Mol. Psychiatry 2000 5 410 417 10.1038/sj.mp.4000736 10889552
43. Tiwari A.K. Deshpande S.N. Lerer B. Nimgaonkar V.L. Thelma B.K. Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism Pharm. J. 2007 7 305 311 10.1038/sj.tpj.6500415 16969362
44. Kroon L.A. Drug interactions with smoking Am. J. Health Syst. Pharm. 2007 64 1917 1921 10.2146/ajhp060414 17823102
45. Du J. Zhang A. Wang L. Xuan J. Yu L. Che R. Li X. Gu N. Lin Z. Feng G. Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients J. Psychopharmacol. 2010 24 1115 1120 10.1177/0269881109104932 19395426
46. Xing Q. Gao R. Li H. Feng G. Xu M. Duan S. Meng J. Zhang A. Qin S. He L. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients Pharmacogenomics 2006 7 987 993 10.2217/14622416.7.7.987 17054409
47. Bozina N. Kuzman M.R. Medved V. Jovanovic N. Sertic J. Hotujac L. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients J. Psychiatr. Res. 2008 42 89 97 10.1016/j.jpsychires.2006.10.002 17113599
48. Lee S.T. Ryu S. Kim S.R. Kim M.J. Kim S. Kim J.W. Lee S.Y. Hong K.S. Association study of 27 annotated genes for clozapine pharmacogenetics: Validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response J. Clin. Psychopharmacol. 2012 32 441 448 10.1097/JCP.0b013e31825ac35c 22722500
49. Schafer M. Rujescu D. Giegling I. Guntermann A. Erfurth A. Bondy B. Moller H.J. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D receptor gene Am. J. Psychiatry 2001 158 802 804 10.1176/appi.ajp.158.5.802 11329406
50. Suzuki A. Kondo T. Otani K. Mihara K. Yasui-Furukori N. Sano A. Koshiro K. Kaneko S. Association of the TaqI A polymorphism of the dopamine D receptor gene with predisposition to neuroleptic malignant syndrome Am. J. Psychiatry 2001 158 1714 1716 10.1176/appi.ajp.158.10.1714 11579007
51. Vijayan N.N. Bhaskaran S. Koshy L.V. Natarajan C. Srinivas L. Nair C.M. Allencherry P.M. Banerjee M. Association of dopamine receptor polymorphisms with schizophrenia and antipsychotic response in a South Indian population Behav. Brain Funct. 2007 33 4 10.1186/1744-9081-3-34
52. Dahmen N. Muller M.J. Germeyer S. Rujescu D. Anghelescu I. Hiemke C. Wetzel H. Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients Schizophr. Res. 2001 49 223 225 10.1016/S0920-9964(99)00147-4 11428346
53. Lencz T. Robinson D.G. Xu K. Ekholm J. Sevy S. Gunduz-Bruce H. Woerner M.G. Kane J.M. Goldman D. Malhotra A.K. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients Am. J. Psychiatry 2006 163 529 531 10.1176/appi.ajp.163.3.529 16513877
54. Cohen B.M. Ennulat D.J. Centorrino F. Matthysse S. Konieczna H. Chu H.M. Cherkerzian S. Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs Psychopharmacology 1999 141 6 10 10.1007/s002130050799 9952058
55. Szekeres G. Keri S. Juhasz A. Rimanoczy A. Szendi I. Czimmer C. Janka Z. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia Am. J. Med. Genet. B Neuropsychiatr. Genet. 2004 124 1 5 10.1002/ajmg.b.20045 14681904
56. Reynolds G.P. Yao Z. Zhang X. Sun J. Zhang Z. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response Eur. Neuropsychopharmacol. 2005 15 143 151 10.1016/j.euroneuro.2004.07.001 15695058
57. Anttila S. Illi A. Kampman O. Mattila K.M. Lehtimaki T. Leinonen E. Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics Pharmacogenetics 2004 14 303 307 10.1097/00008571-200405000-00005 15115916
58. Molero P. Ortuno F. Zalacain M. Patino-Garcia A. Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: Influence on the severity of psychotic symptoms and on the response to neuroleptic treatment Pharm. J. 2007 7 418 426 10.1038/sj.tpj.6500441 17363961
59. Weickert T.W. Goldberg T.E. Mishara A. Apud J.A. Kolachana B.S. Egan M.F. Weinberger D.R. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications Biol. Psychiatry 2004 56 677 682 10.1016/j.biopsych.2004.08.012 15522252
60. Woodward N.D. Jayathilake K. Meltzer H.Y. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia Schizophr. Res. 2007 90 86 96 10.1016/j.schres.2006.10.002 17123785
61. Joober R. Benkelfat C. Brisebois K. Toulouse A. Turecki G. Lal S. Bloom D. Labelle A. Lalonde P. Fortin D. T102C polymorphism in the 5HT2A gene and schizophrenia: Relation to phenotype and drug response variability J. Psychiatry Neurosci. JPN 1999 24 141 146 10212557
62. Arranz M.J. Munro J. Owen M.J. Spurlock G. Sham P.C. Zhao J. Kirov G. Collier D.A. Kerwin R.W. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine Mol. Psychiatry 1998 3 61 66 10.1038/sj.mp.4000348 9491814
63. Hamdani N. Bonniere M. Ades J. Hamon M. Boni C. Gorwood P. Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics Neurosci. Lett. 2005 377 69 74 10.1016/j.neulet.2004.11.070 15722190
64. Benmessaoud D. Hamdani N. Boni C. Ramoz N. Hamon M. Kacha F. Gorwood P. Excess of transmission of the G allele of the −1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics BMC Psychiatry 2008 84 1 7
65. Müller D.J. De Luca V. Sicard T. King N. Hwang R. Volavka J. Czobor P. Sheitman B.B. Lindenmayer J.P. Citrome L. Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol. 2005 15 525 531 10.1016/j.euroneuro.2005.02.001 16139171
66. Kohlrausch F.B. Salatino-Oliveira A. Gama C.S. Lobato M.I. Belmonte-de-Abreu P. Hutz M.H. G-protein gene 825C>T polymorphism is associated with response to clozapine in Brazilian schizophrenics Pharmacogenomics 2008 9 1429 1436 10.2217/14622416.9.10.1429 18855531
67. Arranz M.J. Bolonna A.A. Munro J. Curtis C.J. Collier D.A. Kerwin R.W. The serotonin transporter and clozapine response Mol. Psychiatry 2000 5 124 125 10.1038/sj.mp.4000652 10822334
68. Lee H.Y. Kim D.J. Lee H.J. Choi J.E. Kim Y.K. No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR) with characteristics and treatment response to atypical antipsychotic agents in schizophrenic patients Prog. Neuropsychopharmacol. Biol. Psychiatry 2009 33 276 280 10.1016/j.pnpbp.2008.11.013 19059448
69. Vázquez-Bourgon J. Arranz M.J. Mata I. Pelayo-Terán J.M. Pérez-Iglesias R. Medina-González L. Carrasco-Marín E. Vázquez-Barquero J.L. Crespo-Facorro B. Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis Psychiatry Res. 2010 175 189 194 10.1016/j.psychres.2008.12.011 20031235
70. Strous R.D. Greenbaum L. Kanyas K. Merbl Y. Horowitz A. Karni O. Viglin D. Olender T. Deshpande S.N. Lancet D. Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication Int. J. Neuropsychopharmacol. 2007 10 321 333 16734940
71. Krebs M.O. Guillin O. Bourdell M.C. Schwartz J.C. Olie J.P. Poirier M.F. Sokoloff P. Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia Mol. Psychiatry 2000 5 558 562 10.1038/sj.mp.4000749 11032392
72. Zai G. Arnold P.D. Burroughs E. Richter M.A. Kennedy J.L. Tumor necrosis factor-alpha gene is not associated with obsessive-compulsive disorder Psychiatr. Genet. 2006 16 43 45 10.1097/01.ypg.0000185026.12687.92 16395130
73. Kampman O. Anttila S. Illi A. Saarela M. Rontu R. Mattila K.M. Leinonen E. Lehtimaki T. Neuregulin genotype and medication response in Finnish patients with schizophrenia Neuroreport 2004 15 2517 2520 10.1097/00001756-200411150-00017 15538186
74. Joober R. Benkelfat C. Lal S. Bloom D. Labelle A. Lalonde P. Turecki G. Rozen R. Rouleau G.A. Association between the methylenetetrahydrofolate reductase 677C-->T missense mutation and schizophrenia Mol. Psychiatry 2000 5 323 326 10.1038/sj.mp.4000724 10889537
75. Hamdani N. Tabeze J.P. Ramoz N. Ades J. Hamon M. Sarfati Y. Boni C. Gorwood P. The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia Eur. Neuropsychopharmacol. 2008 18 34 40 10.1016/j.euroneuro.2007.05.005 17669634
76. Mancama D. Arranz M.J. Munro J. Osborne S. Makoff A. Collier D. Kerwin R. Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response Neurosci. Lett. 2002 333 207 211 10.1016/S0304-3940(02)00178-7 12429384
77. Zuo L. Luo X. Kranzler H.R. Lu L. Rosenheck R.A. Cramer J. van Kammen D.P. Erdos J. Charney D.S. Krystal J. Association study of DTNBP1 with schizophrenia in a US sample Psychiatr. Genet. 2009 19 292 304 10.1097/YPG.0b013e32832a50bc 19862852
78. Souza R.P. Ismail P. Meltzer H.Y. Kennedy J.L. Variants in the oxytocin gene and risk for schizophrenia Schizophr. Res. 2010 121 279 280 10.1016/j.schres.2010.04.019 20547038
79. Souza R.P. de Luca V. Remington G. Lieberman J.A. Meltzer H.Y. Kennedy J.L. Wong A.H. Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia Psychopharmacology 2010 210 347 354 10.1007/s00213-010-1829-4 20369355
80. Potkin S.G. Basile V.S. Jin Y. Masellis M. Badri F. Keator D. Wu J.C. Alva G. Carreon D.T. Bunney W.E. Jr. D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine Mol. Psychiatry 2003 8 109 113 10.1038/sj.mp.4001191 12556915
81. Hwang R. Shinkai T. De Luca V. Ni X. Potkin S.G. Lieberman J.A. Meltzer H.Y. Kennedy J.L. Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response J. Psychopharmacol. 2007 21 718 727 10.1177/0269881106072341 17092969
82. Hwang R. Shinkai T. De Luca V. Müller D.J. Ni X. Macciardi F. Potkin S. Lieberman J.A. Meltzer H.Y. Kennedy J.L. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations Psychopharmacology 2005 181 179 187 10.1007/s00213-005-2223-5 15830237
83. Hwang R. Shinkai T. Deluca V. Macciardi F. Potkin S. Meltzer H.Y. Kennedy J.L. Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment Eur. Neuropsychopharmacol. 2006 16 248 259 10.1016/j.euroneuro.2005.09.004 16278074
84. Shaikh S. Collier D.A. Sham P.C. Ball D. Aitchison K. Vallada H. Smith I. Gill M. Kerwin R.W. Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia Hum. Genet. 1996 97 714 719 10.1007/BF02346178 8641685
85. Scharfetter J. Chaudhry H.R. Hornik K. Fuchs K. Sieghart W. Kasper S. Aschauer H.N. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients Eur. Neuropsychopharmacol. 1999 10 17 20 10.1016/S0924-977X(99)00044-9 10647091
86. Zhao A.L. Zhao J.P. Zhang Y.H. Xue Z.M. Chen J.D. Chen X.G. Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine Int. J. Neurosci. 2005 115 1539 1547 10.1080/00207450590957863 16223700
87. Shaikh S. Collier D. Kerwin R.W. Pilowsky L.S. Gill M. Xu W.M. Thornton A. Dopamine D4 receptor subtypes and response to clozapine Lancet 1993 341 116 10.1016/0140-6736(93)92594-J
88. Hwang R. Zai C. Tiwari A. Müller D.J. Arranz M.J. Morris A.G. McKenna P.J. Munro J. Potkin S.G. Lieberman J.A. Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: Exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant Pharmacogenomics J. 2010 10 200 218 10.1038/tpj.2009.65 20029384
89. Rao P.A. Pickar D. Gejman P.V. Ram A. Gershon E.S. Gelernter J. Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine Arch. Gen. Psychiatry 1994 51 912 917 10.1001/archpsyc.1994.03950110072009 7944879
90. Rietschel M. Naber D. Oberländer H. Holzbach R. Fimmers R. Eggermann K. Möller H.J. Propping P. Nöthen M.M. Efficacy and side-effects of clozapine: Testing for association with allelic variation in the dopamine D4 receptor gene Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 1996 15 491 496 10.1016/S0893-133X(96)00090-5
91. Xu M. Xing Q. Li S. Zheng Y. Wu S. Gao R. Yu L. Guo T. Yang Y. Liu J. Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia Prog. Neuropsychopharmacol. Biol. Psychiatry 2010 34 1026 1032 10.1016/j.pnpbp.2010.05.017 20580759
92. Yu Y.W. Tsai S.J. Yang K.H. Lin C.H. Chen M.C. Hong C.J. Evidence for an association between polymorphism in the serotonin-2A receptor variant (102T/C) and increment of N100 amplitude in schizophrenics treated with clozapine Neuropsychobiology 2001 43 79 82 10.1159/000054871 11174050
93. Masellis M. Basile V. Meltzer H.Y. Lieberman J.A. Sevy S. Macciardi F.M. Cola P. Howard A. Badri F. Nöthen M.M. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 1998 19 123 132 10.1016/S0893-133X(98)00007-4
94. Arranz M. Collier D. Sodhi M. Ball D. Roberts G. Price J. Sham P. Kerwin R. Association between clozapine response and allelic variation in 5-HT2A receptor gene Lancet 1995 346 281 282 10.1016/S0140-6736(95)92168-0 7630250
95. Arranz M.J. Collier D.A. Munro J. Sham P. Kirov G. Sodhi M. Roberts G. Price J. Kerwin R.W. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine Neurosci. Lett. 1996 217 177 178 10.1016/0304-3940(96)13094-9 8916101
96. Sodhi M.S. Arranz M.J. Curtis D. Ball D.M. Sham P. Roberts G.W. Price J. Collier D.A. Kerwin R.W. Association between clozapine response and allelic variation in the 5-HT2C receptor gene Neuroreport 1995 7 169 172 10.1097/00001756-199512000-00041 8742444
97. Arranz M.J. Munro J. Birkett J. Bolonna A. Mancama D. Sodhi M. Lesch K.P. Meyer J.F. Sham P. Collier D.A. Pharmacogenetic prediction of clozapine response Lancet 2000 355 1615 1616 10.1016/S0140-6736(00)02221-2 10821369
98. Kohlrausch F.B. Salatino-Oliveira A. Gama C.S. Lobato M.I. Belmonte-de-Abreu P. Hutz M.H. Influence of serotonin transporter gene polymorphisms on clozapine response in Brazilian schizophrenics J. Psychiatr. Res. 2010 44 1158 1162 10.1016/j.jpsychires.2010.04.003 20452607
99. Nothen M.M. Rietschel M. Erdmann J. Oberlander H. Moller H.J. Nober D. Propping P. Genetic variation of the 5-HT2A receptor and response to clozapine Lancet 1995 346 908 909 10.1016/S0140-6736(95)92756-5
100. Rietschel M. Naber D. Fimmers R. Moller H.J. Propping P. Nothen M.M. Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor Neuroreport 1997 8 1999 2003 10.1097/00001756-199705260-00040 9223092
101. Malhotra A.K. Goldman D. Ozaki N. Breier A. Buchanan R. Pickar D. Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine Am. J. Psychiatry 1996 153 1092 1094 8678181
102. Malhotra A.K. Goldman D. Ozaki N. Rooney W. Clifton A. Buchanan R.W. Breier A. Pickar D. Clozapine response and the 5HT2C Cys23Ser polymorphism Neuroreport 1996 7 2100 2102 10.1097/00001756-199609020-00007 8930967
103. Masellis M. Basile V.S. Meltzer H.Y. Lieberman J.A. Sevy S. Goldman D.A. Hamblin M.W. Macciardi F.M. Kennedy J.L. Lack of association between the T-->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia Schizophr. Res. 2001 47 49 58 10.1016/S0920-9964(00)00016-5 11163544
104. Masellis M. Paterson A.D. Badri F. Lieberman J.A. Meltzer H.Y. Cavazzoni P. Kennedy J.L. Genetic variation of 5-HT2A receptor and response to clozapine Lancet 1995 346 1108 10.1016/S0140-6736(95)91785-3
105. Birkett J.T. Arranz M.J. Munro J. Osbourn S. Kerwin R.W. Collier D.A. Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response Neuroreport 2000 11 2017 2020 10.1097/00001756-200006260-00042 10884063
106. Gutiérrez B. Arranz M.J. Huezo-Diaz P. Dempster D. Matthiasson P. Travis M. Munro J. Osborne S. Kerwin R.W. Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response Schizophr. Res. 2002 58 93 97 10.1016/S0920-9964(02)00205-0 12363396
107. Kaiser R. Tremblay P.B. Schmider J. Henneken M. Dettling M. Müller-Oerlinghausen B. Uebelhack R. Roots I. Brockmöller J. Serotonin transporter polymorphisms: No association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia Mol. Psychiatry 2001 6 179 185 10.1038/sj.mp.4000821 11317220
108. Bolonna A.A. Arranz M.J. Munro J. Osborne S. Petouni M. Martinez M. Kerwin R.W. No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response Neurosci. Lett. 2000 280 65 68 10.1016/S0304-3940(99)01000-9 10696813
109. Bolonna A.A. Kerwin R.W. Munro J. Arranz M.J. Makoff A.J. Polymorphisms in the genes for mGluR types 7 and 8: Association studies with schizophrenia Schizophr. Res. 2001 47 99 103 10.1016/S0920-9964(99)00235-2 11163549
110. Tsai S.J. Wang Y.C. Yu Younger W.Y. Lin C.H. Yang K.H. Hong C.J. Association analysis of polymorphism in the promoter region of the alpha2a-adrenoceptor gene with schizophrenia and clozapine response Schizophr. Res. 2001 49 53 58 10.1016/S0920-9964(00)00127-4 11343863
111. Lane H.Y. Lee C.C. Chang Y.C. Lu C.T. Huang C.H. Chang W.H. Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function Int. J. Neuropsychopharmacol. 2004 7 461 470 10.1017/S1461145704004389 15140279
112. Itokawa M. Arinami T. Toru M. Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: Ser311Cys polymorphisms of the dopamine D2-receptor gene and schizophrenia J. Pharmacol. Sci. 2010 114 1 5 10.1254/jphs.10R07FM 20716857
113. Ikeda M. Yamanouchi Y. Kinoshita Y. Kitajima T. Yoshimura R. Hashimoto S. O’Donovan M.C. Nakamura J. Ozaki N. Iwata N. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia Pharmacogenomics 2008 9 1437 1443 10.2217/14622416.9.10.1437 18855532
114. Xing Q. Qian X. Li H. Wong S. Wu S. Feng G. Duan S. Xu M. Gao R. Qin W. The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients The Int. J. Neuropsychopharmacol. 2007 10 631 637 10.1017/S146114570600719X 17105675
115. Gupta M. Bhatnagar P. Grover S. Kaur H. Baghel R. Bhasin Y. Chauhan C. Verma B. Manduva V. Mukherjee O. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment Pharmacogenomics 2009 10 385 397 10.2217/14622416.10.3.385 19290789
116. Fijal B.A. Stauffer V.L. Kinon B.J. Conley R.R. Hoffmann V.P. Witte M.M. Zhao F. Houston J.P. Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone J. Clin. Psychiatry 2012 73 367 371 10.4088/JCP.10m06507 21813073
117. Lane H.Y. Chang Y.C. Chiu C.C. Chen M.L. Hsieh M.H. Chang W.H. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene Am. J. Psychiatry 2002 159 1593 1595 10.1176/appi.ajp.159.9.1593 12202283
118. Kim B. Choi E.Y. Kim C.Y. Song K. Joo Y.H. Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting Hum. Psychopharmacol. 2008 23 61 67 10.1002/hup.897 17924589
119. Yamanouchi Y. Iwata N. Suzuki T. Kitajima T. Ikeda M. Ozaki N. Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone Pharm. J. 2003 3 356 361 10.1038/sj.tpj.6500211 14610521
120. Xu M.Q. St Clair D. Feng G.Y. Lin Z.G. He G. Li X. He L. BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population Pharmacogenet. Genom. 2008 18 449 457 10.1097/FPC.0b013e3282f85e26 18408624
121. Fijal B.A. Kinon B.J. Kapur S. Stauffer V.L. Conley R.R. Jamal H.H. Kane J.M. Witte M.M. Houston J.P. Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia Pharm. J. 2009 9 311 318 10.1038/tpj.2009.24 19451915
122. Zalsman G. Frisch A. Lev-Ran S. Martin A. Michaelovsky E. Bensason D. Gothelf D. Nahshoni E. Tyano S. Weizman A. DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: A pilot pharmacogenetic study Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol. 2003 13 183 185 10.1016/S0924-977X(03)00006-3
123. Lane H.Y. Hsu S.K. Liu Y.C. Chang Y.C. Huang C.H. Chang W.H. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response J. Clin. Psychopharmacol. 2005 25 6 11 10.1097/01.jcp.0000150226.84371.76 15643094
124. Liu B.C. Zhang J. Wang L. Li X.W. Wang Y. Wei Z.Y. Ji J. Yang F.P. Wan C.L. Xu Y.F. HTR2C promoter polymorphisms are associated with risperidone efficacy in Chinese female patients Pharmacogenomics 2010 11 685 692 10.2217/pgs.10.23 20415561
125. Gu B. Wang L. Zhang A.P. Ma G. Zhao X.Z. Li H.F. Feng G.Y. He L. Xing Q.H. Association between a polymorphism of the HTR3A gene and therapeutic response to risperidone treatment in drug-naive Chinese schizophrenia patients Pharm. Genom. 2008 18 721 727 10.1097/FPC.0b013e32830500e2 18622264
126. Lane H.Y. Lin C.C. Huang C.H. Chang Y.C. Hsu S.K. Chang W.H. Risperidone response and 5-HT6 receptor gene variance: Genetic association analysis with adjustment for nongenetic confounders Schizophr. Res. 2004 67 63 70 10.1016/j.schres.2003.08.006 14741325
127. Wang L. Yu L. He G. Zhang J. Zhang A.P. Du J. Tang R.Q. Zhao X.Z. Ma J. Xuan J.K. Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients Neurosci. Lett. 2007 414 1 4 10.1016/j.neulet.2006.09.014 17287080
128. Lane H.Y. Liu Y.C. Huang C.L. Chang Y.C. Wu P.L. Huang C.H. Tsai G.E. RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia J. Clin. Psychopharmacol. 2008 28 64 68 10.1097/jcp.0b013e3181603f5a 18204343
129. Wei Z. Wang L. Xuan J. Che R. Du J. Qin S. Xing Y. Gu B. Yang L. Li H. Association analysis of serotonin receptor 7 gene (HTR7) and risperidone response in Chinese schizophrenia patients Prog. Neuropsychopharmacol. Biol. Psychiatry 2009 33 547 551 10.1016/j.pnpbp.2009.02.008 19233240
130. Staddon S. Arranz M.J. Mancama D. Mata I. Kerwin R.W. Clinical applications of pharmacogenetics in psychiatry Psychopharmacology 2002 162 18 23 10.1007/s00213-002-1084-4 12107612
131. Adams D.H. Close S. Farmen M. Downing A.M. Breier A. Houston J.P. Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder Hum. Psychopharmacol. 2008 23 267 274 10.1002/hup.930 18320559
132. Thomas P. Srivastava V. Singh A. Mathur P. Nimgaonkar V.L. Lerer B. Thelma B.K. Deshpande S.N. Correlates of response to Olanzapine in a North Indian Schizophrenia sample Psychiatry Res. 2008 161 275 283 10.1016/j.psychres.2007.09.010 19000940
133. Bertolino A. Caforio G. Blasi G. De Candia M. Latorre V. Petruzzella V. Altamura M. Nappi G. Papa S. Callicott J.H. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia Am. J. Psychiatry 2004 161 1798 1805 10.1176/ajp.161.10.1798 15465976
134. Bozina N. Medved V. Kuzman M.R. Sain I. Sertic J. Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients J. Psychopharmacol. 2007 21 728 734 10.1177/0269881106072750 17092963
135. Houston J.P. Adams D.H. Kirkwood S.C. Farmen M. Downing A.M. Breier A. Neuroreceptor gene polymorphisms and olanzapine depressive symptom response in schizophrenia J. Clin. Psychopharmacol. 2007 27 520 523 10.1097/JCP.0b013e31814f4d82 17873692
136. Bishop J.R. Ellingrod V.L. Moline J. Miller D. Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment Schizophr. Res. 2005 77 253 260 10.1016/j.schres.2005.04.001 15913960
137. Porcelli S. Lee S.J. Han C. Patkar A.A. Serretti A. Pae C.U. CACNA1C gene and schizophrenia: A case-control and pharmacogenetic study Psychiatr. Genet. 2015 25 163 167 10.1097/YPG.0000000000000092 26049408
138. Nyegaard M. Demontis D. Foldager L. Hedemand A. Flint T.J. Sørensen K.M. Andersen P.S. Nordentoft M. Werge T. Pedersen C.B. CACNA1C (rs1006737) is associated with schizophrenia Mol. Psychiatry 2010 15 119 121 10.1038/mp.2009.69 20098439
139. Natesan S. Kapur S. Antipsychotic therapy over half a century: A tale of discovery from chlorpromazine to aripiprazole Natl. Med. J. India 2012 25 193 195 23278774
140. Kwon J.S. Kim E. Kang D.H. Choi J.S. Yu K.S. Jang I.J. Shin S.G. Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole Eur. Neuropsychopharmacol. 2008 18 897 907 10.1016/j.euroneuro.2008.07.010 18786813
141. Shen Y.C. Chen S.F. Chen C.H. Lin C.C. Chen S.J. Chen Y.J. Luu S.U. Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients J. Psychiatr. Res. 2009 43 600 606 10.1016/j.jpsychires.2008.09.005 18926547
142. Liou Y.J. Lai I.C. Liao D.L. Chen J.Y. Lin C.C. Lin C.Y. Chen C.M. Bai Y.M. Chen T.T. Wang Y.C. The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia Schizophr. Res. 2006 86 323 325 10.1016/j.schres.2006.04.008 16769201
143. Al Hadithy A.F. Wilffert B. Stewart R.E. Looman N.M. Bruggeman R. Brouwers J.R. Matroos G.E. van Os J. Hoek H.W. van Harten P.N. Pharmacogenetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African-Caribbean inpatients: Differences in association with dopamine and serotonin receptors Am. J. Med. Genet. B. Neuropsychiatr. Genet. 2008 147B 890 897 10.1002/ajmg.b.30746 18389501
144. Mo G.H. Lai I.C. Wang Y.C. Chen J.Y. Lin C.Y. Chen T.T. Chen M.L. Liou Y.J. Liao D.L. Bai Y.M. Support for an association of the C939T polymorphism in the human DRD2 gene with tardive dyskinesia in schizophrenia Schizophr. Res. 2007 97 302 304 10.1016/j.schres.2007.06.026 17669630
145. Chen C.H. Wei F.C. Koong F.J. Hsiao K.J. Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia Biol. Psychiatry 1997 41 827 829 10.1016/S0006-3223(96)00543-4 9084902
146. Gassó P. Mas S. Crescenti A. Alvarez S. Parramon G. Garcia-Rizo C. Parellada E. Bernardo M. Lafuente A. Lack of association between antipsychotic-induced extrapyramidal symptoms and polymorphisms in dopamine metabolism and transport genes Psychiatry Res. 2010 175 173 175 10.1016/j.psychres.2009.07.006 19892410
147. Srivastava V. Varma P.G. Prasad S. Semwal P. Nimgaonkar V.L. Lerer B. Deshpande S.N. Bk T. Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms Pharmacogenet. Genom. 2006 16 111 117 10.1097/01.fpc.0000184957.98150.0f
148. Lafuente A. Bernardo M. Mas S. Crescenti A. Aparici M. Gasso P. Deulofeu R. Mane A. Catalan R. Carne X. Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders Psychiatry Res. 2008 161 131 141 10.1016/j.psychres.2007.08.002 18922583
149. Mihara K. Suzuki A. Kondo T. Nagashima U. Ono S. Otani K. Kaneko S. No relationship between Taq1 a polymorphism of dopamine D receptor gene and extrapyramidal adverse effects of selective dopamine D antagonists, bromperidol, and nemonapride in schizophrenia: A preliminary study Am. J. Med. Genet. 2000 96 422 424 10.1002/1096-8628(20000612)96:3<422::AID-AJMG35>3.0.CO;2-5 10898926
150. Lattuada E. Cavallaro R. Serretti A. Lorenzi C. Smeraldi E. Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: An association study with repeated assessment Int. J. Neuropsychopharmacol. 2004 7 489 493 10.1017/S1461145704004614 15383158
151. Mihara K. Kondo T. Suzuki A. Yasui N. Ono S. Otani K. Kaneko S. No relationship between-−141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: A preliminary study Psychiatry Res. 2001 101 33 38 10.1016/S0165-1781(00)00247-X 11223117
152. Chong S.A. Tan E.C. Tan C.H. Smoking and tardive dyskinesia: Lack of involvement of the CYP1A2 gene J. Psychiatry Neurosci. 2003 28 185 189 12790158
153. Hori H. Ohmori O. Shinkai T. Kojima H. Nakamura J. Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia Am. J. Med. Genet. 2001 105 774 778 10.1002/ajmg.10045 11803529
154. Kaiser R. Tremblay P.B. Klufmoller F. Roots I. Brockmoller J. Relationship between adverse effects of antipsychotic treatment and dopamine D receptor polymorphisms in patients with schizophrenia Mol. Psychiatry 2002 7 695 705 10.1038/sj.mp.4001054 12192613
155. Dolzan V. Plesnicar B.K. Serretti A. Mandelli L. Zalar B. Koprivsek J. Breskvar K. Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007 144 809 815 10.1002/ajmg.b.30544 17455212
156. Gasso P. Mas S. Bernardo M. Alvarez S. Parellada E. Lafuente A. A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms Pharm. J. 2009 9 404 410 10.1038/tpj.2009.26 19506579
157. Steen V.M. Lovlie R. MacEwan T. McCreadie R.G. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients Mol. Psychiatry 1997 2 139 145 10.1038/sj.mp.4000249 9106238
158. Segman R. Neeman T. Heresco-Levy U. Finkel B. Karagichev L. Schlafman M. Dorevitch A. Yakir A. Lerner A. Shelevoy A. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia Mol. Psychiatry 1999 4 247 253 10.1038/sj.mp.4000511 10395214
159. Lerer B. Segman R.H. Fangerau H. Daly A.K. Basile V.S. Cavallaro R. Aschauer H.N. McCreadie R.G. Ohlraun S. Ferrier N. Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 2002 27 105 119 10.1016/S0893-133X(02)00293-2
160. Liao D.L. Yeh Y.C. Chen H.M. Chen H. Hong C.J. Tsai S.J. Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients Neuropsychobiology 2001 44 95 98 10.1159/000054924 11490179
161. Woo S.I. Kim J.W. Rha E. Han S.H. Hahn K.H. Park C.S. Sohn J.W. Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics Psychiatry Clin. Neurosci. 2002 56 469 474 10.1046/j.1440-1819.2002.01038.x 12109967
162. Eichhammer P. Albus M. Borrmann-Hassenbach M. Schoeler A. Putzhammer A. Frick U. Klein H.E. Rohrmeier T. Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: A generalization of Steen’s study on DRD3 and tardive dyskinesia Am. J. Med. Genet. 2000 96 187 191 10.1002/(SICI)1096-8628(20000403)96:2<187::AID-AJMG13>3.0.CO;2-8 10893495
163. Rizos E.N. Nikolaos S. Katsantoni E. Lazou V. Sakellaropoulos K. Kastania A. Kossida S. Chatzigeorgiou K.-S. Arsenis G. Zerva L. Association of the dopamine D3 receptor Ser9Gly and of the serotonin 2C receptor gene polymorphisms with tardive dyskinesia in Greeks with chronic schizophrenic disorder Psychiatr. Genet. 2009 19 106 107 10.1097/YPG.0b013e32832080ad 19106782
164. Mihara K. Kondo T. Higuchi H. Takahashi H. Yoshida K. Shimizu T. Kaneko S. Tardive dystonia and genetic polymorphisms of cytochrome P4502D6 and dopamine D2 and D3 receptors: A preliminary finding Am. J. Med. Genet. 2002 114 693 695 10.1002/ajmg.10602 12210290
165. Liou Y.J. Liao D.L. Chen J.Y. Wang Y.C. Lin C.C. Bai Y.M. Yu S.C. Lin M.W. Lai I.C. Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients Neuromolecular Med. 2004 5 243 251 10.1385/NMM:5:3:243 15626824
166. Rietschel M. Krauss H. Müller D.J. Schulze T.G. Knapp M. Marwinski K. Maroldt A.O. Paus S. Grünhage F. Propping P. Dopamine D3 receptor variant and tardive dyskinesia Eur. Arch. Psychiatry Clin. Neurosci. 2002 250 31 35 10.1007/PL00007536
167. Garcia-Barcelo M.M. Lam L.C. Ungvari G.S. Lam V.K. Tang W.K. Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients J. Neural. Transm. 2001 108 671 677 10.1007/s007020170044 11478419
168. Zai C.C. Tiwari A.K. De Luca V. Müller D.J. Bulgin N. Hwang R. Zai G.C. King N. Voineskos A.N. Meltzer H.Y. Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol. 2009 19 317 328 10.1016/j.euroneuro.2009.01.001
169. Chong S.A. Tan E.C. Tan C.H. Mythily Chan Y.H. Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003 116 51 54 10.1002/ajmg.b.10004
170. Wilffert B. Al Hadithy A.F. Sing V.J. Matroos G. Hoek H.W. van Os J. Bruggeman R. Brouwers J.R. van Harten P.N. The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX J. Psychopharmacol. 2009 23 652 659 10.1177/0269881108091594 18562401
171. Srivastava V. Deshpande S.N. Nimgaonkar V.L. Lerer B. Thelma B. Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: Role of metabolic pathway genes Pharmacogenomics 2008 9 1055 1068 10.2217/14622416.9.8.1055 18681781
172. Herken H. Erdal M.E. Boke O. Savas H.A. Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-o-methyltransferase gene Eur. Psychiatry 2003 18 77 81 10.1016/S0924-9338(03)00005-1 12711403
173. Lai I.C. Wang Y.C. Lin C.C. Bai Y.M. Liao D.L. Yu S.C. Lin C.Y. Chen J.Y. Liou Y.J. Negative association between catechol-O-methyltransferase (COMT) gene Val158Met polymorphism and persistent tardive dyskinesia in schizophrenia J. Neural Transm. 2005 112 1107 1113 10.1007/s00702-004-0252-6 15583953
174. Matsumoto C. Shinkai T. Hori H. Ohmori O. Nakamura J. Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia Psychiatry Res. 2004 127 1 7 10.1016/j.psychres.2004.03.011 15261699
175. Lafuente A. Bernardo M. Mas S. Crescenti A. Aparici M. Gasso P. Catalan R. Mateos J.J. Lomeña F. Parellada E. Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics Schizophr. Res. 2007 90 115 122 10.1016/j.schres.2006.09.031 17150335
176. Greenbaum L. Strous R.D. Kanyas K. Merbl Y. Horowitz A. Karni O. Katz E. Kotler M. Olender T. Deshpande S.N. Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication Pharm. Genom. 2007 17 519 528 10.1097/FPC.0b013e32800ffbb4 17558307
177. Greenbaum L. Smith R.C. Rigbi A. Strous R. Teltsh O. Kanyas K. Korner M. Lancet D. Ben-Asher E. Lerer B. Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: Protective role of a functional polymorphism in the 3’-untranslated region Pharm. J. 2009 9 103 110 10.1038/tpj.2008.6
178. Higa M. Ohnuma T. Maeshima H. Hatano T. Hanzawa R. Shibata N. Sakai Y. Suzuki T. Arai H. Association analysis between functional polymorphism of the rs4606 SNP in the RGS2 gene and antipsychotic-induced Parkinsonism in Japanese patients with schizophrenia: Results from the Juntendo University Schizophrenia Projects (JUSP) Neurosci. Lett. 2010 469 55 59 10.1016/j.neulet.2009.11.043 19931593
179. Tan E.C. Chong S.A. Mahendran R. Dong F. Tan C.H. Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor Biol Psychiatry 2001 50 144 147 10.1016/S0006-3223(01)01076-9 11526996
180. Segman R.H. Heresco-Levy U. Finkel B. Goltser T. Shalem R. Schlafman M. Dorevitch A. Yakir A. Greenberg D. Lerner A. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia Mol. Psychiatry 2001 6 225 229 10.1038/sj.mp.4000842 11317227
181. Deshpande S.N. Varma P.G. Semwal P. Rao A.R. Bhatia T. Nimgaonkar V.L. Lerer B. Thelma B.K.I.I. Serotonin receptor gene polymorphisms and their association with tardive dyskinesia among schizophrenia patients from North India Psychiatr Genet. 2005 15 157 158 10.1097/00041444-200509000-00002 16094246
182. Basile V.S. Ozdemir V. Masellis M. Meltzer H.Y. Lieberman J.A. Potkin S.G. Macciardi F.M. Petronis A. Kennedy J.L. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia Mol. Psychiatry 2001 6 230 234 10.1038/sj.mp.4000847 11317228
183. Zhang Z.J. Zhang X.B. Sha W.W. Zhang X.B. Reynolds G.P. Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia Mol. Psychiatry 2002 7 670 671 10.1038/sj.mp.4001052 12192608
184. Segman R.H. Heresco-Levy U. Finkel B. Inbar R. Neeman T. Schlafman M. Dorevitch A. Yakir A. Lerner A. Goltser T. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: Additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility Psychopharmacology 2000 152 408 413 10.1007/s002130000521 11140333
185. Segman R.H. Lerer B. Age and the relationship of dopamine D3, serotonin 2C and serotonin 2A receptor genes to abnormal involuntary movements in chronic schizophrenia Mol. Psychiatry 2002 7 137 139 10.1038/sj.mp.4000960 11840306
186. Ohmori O. Shinkai T. Hori H. Nakamura J. Genetic association analysis of 5-HT receptor gene polymorphism (267C/T) with tardive dyskinesia Psychiatry Res. 2002 110 97 102 10.1016/S0165-1781(02)00095-1 12057822
187. Chong S.A. Tan E.C. Tan C.H. Mahendren R. Tay A.H. Chua H.C. Tardive dyskinesia is not associated with the serotonin gene polymorphism (5-HTTLPR) in Chinese Am. J. Med. Genet. 2000 96 712 715 10.1002/1096-8628(20001204)96:6<712::AID-AJMG2>3.0.CO;2-U 11121166
188. Park S.W. Lee J.G. Kong B.G. Lee S.J. Lee C.H. Kim J.I. Kim Y.H. Genetic association of BDNF val66met and GSK-3beta-50T/C polymorphisms with tardive dyskinesia Psychiatry Clin. Neurosci. 2009 63 433 439 10.1111/j.1440-1819.2009.01976.x 19457211
189. Kastelic M. Koprivsek J. Plesnicar B.K. Serretti A. Mandelli L. Locatelli I. Grabnar I. Dolzan V. MDR1 gene polymorphisms and response to acute risperidone treatment Prog. Neuropsychopharmacol. Biol. Psychiatry 2010 34 387 392 10.1016/j.pnpbp.2010.01.005 20060871
190. Zhang Z. Zhang X. Hou G. Sha W. Reynolds G.P. The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism J. Psychiatr. Res. 2002 36 317 324 10.1016/S0022-3956(02)00007-9 12127599
191. Pae C.U. Kim T.S. Patkar A.A. Kim J.J. Lee C.U. Lee S.J. Jun T.Y. Lee C. Paik I.H. Manganese superoxide dismutase (MnSOD: Ala-9Val) gene polymorphism may not be associated with schizophrenia and tardive dyskinesia Psychiatry Res. 2007 153 77 81 10.1016/j.psychres.2006.04.011 17582511
192. Liu H. Wang C. Chen P.H. Zhang B.S. Zheng Y.L. Zhang C.X. Meng H.Q. Wang Y. Chen D.C. Xiu M.H. Association of the manganese superoxide dismutase gene Ala-9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients. Prog Neuro Psychopharmacol. Biol. Psychiatry 2010 34 692 696 10.1016/j.pnpbp.2010.03.026 20346996
193. Wang Y.C. Liou Y.J. Liao D.L. Bai Y.M. Lin C.C. Yu S.C. Chen J.Y. Association analysis of a neural nitric oxide synthase gene polymorphism and antipsychotics-induced tardive dyskinesia in Chinese schizophrenic patients J. Neural. Transm. 2004 111 623 629 10.1007/s00702-004-0118-y 15088155
194. Shinkai T. Ohmori O. Matsumoto C. Hori H. Kennedy J.L. Nakamura J. Genetic association analysis of neuronal nitric oxide synthase gene polymorphism with tardive dyskinesia Neuromolecular. Med. 2004 5 163 170 10.1385/NMM:5:2:163 15075442
195. Liou Y.J. Wang Y.C. Lin C.C. Bai Y.M. Lai I.C. Liao D.L. Chen J.Y. Association analysis of NAD(P) Hratioquinone oxidoreductase (NQO1) Pro187Ser genetic polymorphism and tardive dyskinesia in patients with schizophrenia in Taiwan Int. J. Neuropsychopharmacol. 2005 8 483 486 10.1017/S1461145705005262 15836802
196. Shinkai T. De Luca V. Hwang R. Matsumoto C. Hori H. Ohmori O. Remington G. Meltzer H.Y. Lieberman J.A. Potkin S.G. Association study between a functional glutathione S-transferase (GSTP1) gene polymorphism (Ile105Val) and tardive dyskinesia Neurosci. Lett. 2005 388 116 120 10.1016/j.neulet.2005.06.038 16039055
197. Shinkai T. Müller D.J. De Luca V. Shaikh S. Matsumoto C. Hwang R. King N. Trakalo J. Potapova N. Zai G. Genetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesia Psychiatry Res. 2006 141 123 128 10.1016/j.psychres.2004.06.023 16413612
198. Liou Y.J. Lai I.C. Lin M.W. Bai Y.M. Lin C.C. Liao D.L. Chen J.Y. Lin C.Y. Wang Y.C. Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia Pharm. Genom. 2006 16 151 157 10.1097/01.fpc.0000184958.05775.66
199. Pae C.U. Yu H.S. Kim J.J. Lee C.U. Lee S.J. Jun T.Y. Lee C. Paik I.H. Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia Int. J. Neuropsychopharmacol. 2004 7 495 500 10.1017/S1461145704004419 15151706
200. Xu M.Q. Xing Q.H. Zheng Y.L. Li S. Gao J.J. He G. Guo T.W. Feng G.Y. Xu F. He L. Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population J. Clin. Psychiatry 2007 68 1358 1367 10.4088/JCP.v68n0906 17915974
201. Saiz P.A. Susce M.T. Clark D.A. Kerwin R.W. Molero P. Arranz M.J. de Leon J. An investigation of the alpha1A-adrenergic receptor gene and antipsychotic-induced side-effects Hum. Psychopharmacol. 2008 23 107 114 10.1002/hup.903 17972277
202. Young R.M. Lawford B.R. Barnes M. Burton S.C. Ritchie T. Ward W.K. Noble E.P. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele Br. J. Psychiatry 2004 1851 47 151 10.1192/bjp.185.2.147 15286066
203. Kirk S.L. Glazebrook J. Grayson B. Neill J.C. Reynolds G.P. Olanzapine-induced weight gain in the rat: Role of 5-HT2C and histamine H1 receptors Psychopharmacology 2009 207 119 125 10.1007/s00213-009-1639-8 19688201
204. Ellingrod V.L. Perry P.J. Ringold J.C. Lund B.C. Bever-Stille K. Fleming F. Holman T.L. Miller D. Weight gain associated with the −759C/T polymorphism of the 5HT2C receptor and olanzapine Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005 134 76 78 10.1002/ajmg.b.20169
205. Godlewska B.R. Olajossy-Hilkesberger L. Ciwoniuk M. Olajossy M. Marmurowska-Michalowska H. Limon J. Landowski J. Olanzapine-induced weight gain is associated with the −759C/T and −697G/C polymorphisms of the HTR2C gene Pharmacogenom. J. 2009 9 234 241 10.1038/tpj.2009.18
206. Reynolds G.P. Zhang Z.J. Zhang X.B. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism Lancet 2002 359 2086 2087 10.1016/S0140-6736(02)08913-4 12086765
207. Reynolds G.P. Zhang Z. Zhang X. Polymorphism of the promoter region of the serotonin 5-HT2C receptor gene and clozapine-induced weight gain Am. J. Psychiatry 2003 160 677 679 10.1176/appi.ajp.160.4.677 12668355
208. Miller D.D. Ellingrod V.L. Holman T.L. Buckley P.F. Arndt S. Clozapine-induced weight gain associated with the 5HT2C receptor−759C/T polymorphism Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005 133 97 100 10.1002/ajmg.b.30115
209. Templeman L.A. Reynolds G.P. Arranz B. San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis Pharmacogenet. Genom. 2005 15 195 200 10.1097/01213011-200504000-00002
210. Ryu S. Cho E.Y. Park T. Oh S. Jang W.S. Kim S.K. Lee D. Hong K.S. −759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment Prog. Neuropsychopharmacol. Biol. Psychiatry 2007 31 673 677 10.1016/j.pnpbp.2006.12.021 17275977
211. Del Castillo N. Zimmerman M.B. Tyler B. Ellingrod V.L. Calarge C. 759C/T Variants of the Serotonin (5-HT2C) Receptor Gene and Weight Gain in Children and Adolescents in Long-Term Risperidone Treatment Clin. Pharmacol. Biopharm. 2013 2 110 24772381
212. De Luca V. Mueller D.J. de Bartolomeis A. Kennedy J.L. Association of the HTR2C gene and antipsychotic induced weight gain: A meta-analysis Int. J. Neuropsychopharmacol. 2007 10 697 704 10.1017/S1461145707007547 17291373
213. Tsai S.J. Hong C.J. Yu Y.W. Lin C.H. −759C/T genetic variation of 5HT2C receptor and clozapine-induced weight gain Lancet 2002 360 1790 10.1016/S0140-6736(02)11705-3
214. Theisen F.M. Hinney A. Bromel T. Heinzel-Gutenbrunner M. Martin M. Krieg J.C. Remschmidt H. Hebebrand J. Lack of association between the −759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals Psychiatr. Genet. 2004 14 139 142 10.1097/00041444-200409000-00003 15318026
215. Park Y.M. Cho J.H. Kang S.G. Choi J.E. Lee S.H. Kim L. Lee H.J. Lack of association between the −759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients J. Clin. Pharm. Ther. 2008 33 55 60 10.1111/j.1365-2710.2008.00872.x 18211617
216. Yevtushenko O.O. Cooper S.J. O’Neill R. Doherty J.K. Woodside J.V. Reynolds G.P. Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia Br. J. Psychiatry 2008 192 424 428 10.1192/bjp.bp.107.041723 18515891
217. Kuzman M.R. Medved V. Bozina N. Hotujac L. Sain I. Bilusic H. The influence of 5-HT2C and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients Psychiatry Res. 2008 160 308 315 10.1016/j.psychres.2007.06.006 18718676
218. Popp J. Leucht S. Heres S. Steimer W. DRD4 48 bp VNTR but not 5-HT2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain Pharmacogenom. J. 2009 9 71 77 10.1038/tpj.2008.5 18332898
219. Hong C.J. Lin C.H. Yu Y.W. Yang K.H. Tsai S.J. Genetic variants of the serotonin system and weight change during clozapine treatment Pharmacogenetics 2001 11 265 268 10.1097/00008571-200104000-00010 11337942
220. Lane H.Y. Liu Y.C. Huang C.L. Chang Y.C. Wu P.L. Lu C.T. Chang W.H. Risperidone-related weight gain: Genetic and nongenetic predictors J. Clin. Psychopharmacol. 2006 26 128 134 10.1097/01.jcp.0000203196.65710.2b 16633140
221. Al-Janabi I. Arranz M.J. Blakemore A.I. Saiz P.A. Susce M.T. Glaser P.E. Clark D. de Leon J. Association study of serotonergic gene variants with antipsychotic-induced adverse reactions Psychiatr. Genet. 2009 19 305 311 10.1097/YPG.0b013e3283328dcd 19829168
222. Zhang Z.J. Yao Z.J. Zhang X.B. Chen J.F. Sun J. Yao H. Hou G. Zhang X.B. No association of antipsychotic agent-induced weight gain with a DA receptor gene polymorphism and therapeutic response Acta Pharmacol. Sin. 2003 24 235 240 12617772
223. Müller D.J. Zai C.C. Sicard M. Remington E. Souza R.P. Tiwari A.K. Hwang R. Likhodi O. Shaikh S. Freeman N. Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain Pharm. J. 2012 12 156 164 10.1038/tpj.2010.65
224. Lencz T. Robinson D.G. Napolitano B. Sevy S. Kane J.M. Goldman D. Malhotra A.K. DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia Pharmacogenet. Genom. 2010 20 569 572 10.1097/FPC.0b013e32833ca24b
225. Chowdhury N.I. Tiwari A.K. Souza R.P. Zai C.C. Shaikh S.A. Chen S. Liu F. Lieberman J.A. Meltzer H.Y. Malhotra A.K. Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene Pharm. J. 2013 13 272 279 10.1038/tpj.2011.66
226. Czerwensky F. Leucht S. Steimer W. MC4R rs489693: A clinical risk factor for second generation antipsychotic-related weight gain? Int. J. Neuropsychopharmacol. 2013 16 2103 2109 10.1017/S1461145713000849 23920449
227. Park Y.M. Chung Y.C. Lee S.H. Lee K.J. Kim H. Byun Y.C. Lim S.W. Paik J.W. Lee H.J. Weight gain associated with the alpha2a-adrenergic receptor -1,291 C/G polymorphism and olanzapine treatment Am. J. Med Genet. Part B Neuropsychiatr. Genet. 2006 141B 394 397 10.1002/ajmg.b.30311
228. Wang Y.C. Bai Y.M. Chen J.Y. Lin C.C. Lai I.C. Liou Y.J. Polymorphism of the adrenergic receptor alpha 2a −1291C>G genetic variation and clozapine-induced weight gain J. Neural Transm. 2005 112 1463 1468 10.1007/s00702-005-0291-7 15795790
229. Sickert L. Muller D.J. Tiwari A.K. Shaikh S. Zai C. De Souza R. De Luca V. Meltzer H.Y. Lieberman J.A. Kennedy J.L. Association of the alpha2A adrenergic receptor−1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans Pharmacogenomics 2009 10 1169 1176 10.2217/pgs.09.43 19604092
230. Liu Y.R. Loh E.W. Lan T.H. Chen S.F. Yu Y.H. Chang Y.H. Huang C.J. Hu T.M. Lin K.M. Yao Y.T. ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics Pharm. J. 2010 10 30 39 10.1038/tpj.2009.55 19918262
231. Calarge C.A. Ellingrod V.L. Zimmerman B. Acion L. Sivitz W.I. Schlechte J.A. Leptin gene −2548G/A variants predict risperidone-associated weight gain in children and adolescents Psychiatr. Genet. 2009 19 320 327 10.1097/YPG.0b013e3283328e06 19873684
232. Zhang X.Y. Tan Y.L. Zhou D.F. Haile C.N. Cao L.Y. Xu Q. Shen Y. Kosten T.A. Kosten T.R. Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population J. Clin. Psychopharmacol. 2007 27 246 251 10.1097/jcp.0b013e3180582412 17502770
233. Kang S.G. Lee H.J. Park Y.M. Choi J.E. Han C. Kim Y.K. Kim S.H. Lee M.S. Joe S.H. Jung I.K. Possible association between the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain Prog. Neuro Psychopharmacol. Biol. Psychiatry 2008 32 160 163 10.1016/j.pnpbp.2007.08.002
234. Gregoor J.G. van der Weide J. Mulder H. Cohen D. van Megen H.J. Egberts A.C. Heerdink E.R. Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication J. Clin. Psychopharmacol. 2009 29 21 25 10.1097/JCP.0b013e31819359be 19142102
235. Le Hellard S. Theisen F.M. Haberhausen M. Raeder M.B. Fernø J. Gebhardt S. Hinney A. Remschmidt H. Krieg J.C. Mehler-Wex C. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: Perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? Mol. Psychiatry 2009 14 308 317 10.1038/sj.mp.4002133 18195716
236. Tiwari A.K. Zai C.C. Meltzer H.Y. Lieberman J.A. Muller D.J. Kennedy J.L. Association study of polymorphisms in insulin induced gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients Hum. Psychopharmacol. 2010 25 253 259 10.1002/hup.1111 20373477
237. Park Y.M. Chung Y.C. Lee S.H. Lee K.J. Kim H. Choi J.E. Kang S.G. Lee M.S. Kim L. Lee H.J. G-protein beta3 Subunit Gene 825C/T Polymorphism Is Not Associated with Olanzapine-Induced Weight Gain in Korean Schizophrenic Patients Psychiatry Investig. 2009 6 39 43 10.4306/pi.2009.6.1.39
238. Tsai S.J. Yu Y.W. Lin C.H. Wang Y.C. Chen J.Y. Hong C.J. Association study of adrenergic beta3 receptor (Trp64Arg) and G-protein beta3 subunit gene (C825T) polymorphisms and weight change during clozapine treatment Neuropsychobiology 2004 50 37 40 10.1159/000077939 15179018
239. Bishop J.R. Ellingrod V.L. Moline J. Miller D. Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia Med. Sci. Monit. 2006 12 47 50
240. Hong C.J. Lin C.H. Yu Y.W. Chang S.C. Wang S.Y. Tsai S.J. Genetic variant of the histamine-1 receptor (glu349asp) and body weight change during clozapine treatment Psychiatr. Genet. 2002 12 169 171 10.1097/00041444-200209000-00009 12218662
241. Tiwari A.K. Rodgers J.B. Sicard M. Zai C.C. Likhodi O. Freeman N. Meltzer H.Y. Lieberman J.A. Kennedy J.L. Müller D.J. Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients Prog. Neuro Psychopharmacol. Biol. Psychiatry 2010 34 1484 1490 10.1016/j.pnpbp.2010.08.009 20732371
242. Clark D. Skrobot O.A. Adebiyi I. Susce M.T. de Leon J. Blakemore A.F. Arranz M.J. Apolipoprotein-E gene variants associated with cardiovascular risk factors in antipsychotic recipients Eur. Psychiatry 2009 24 456 463 10.1016/j.eurpsy.2009.03.003 19541455
243. Zhang X.Y. Zhou D.F. Wu G.Y. Cao L.Y. Tan Y.L. Haile C.N. Li J. Lu L. Kosten T.A. Kosten T.R. BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia Neuropsychopharmacology 2008 33 2200 2205 10.1038/sj.npp.1301619 17987059
244. Tiwari A.K. Zai C.C. Likhodi O. Lisker A. Singh D. Souza R.P. Batra P. Zaidi S.H. Chen S. Liu F. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia Neuropsychopharmacology 2010 35 1315 1324 10.1038/npp.2009.235 20107430
245. Ellingrod V.L. Miller D. Schultz S.K. Wehring H. Arndt S. CYP2D6 polymorphisms and atypical antipsychotic weight gain Psychiatr. Genet. 2002 12 55 58 10.1097/00041444-200203000-00008 11901361
246. Ellingrod V.L. Miller D.D. Taylor S.F. Moline J. Holman T. Kerr J. Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants Schizophr. Res. 2008 98 47 54 10.1016/j.schres.2007.09.030 17976958
247. van Winkel R. Rutten B.P. Peerbooms O. Peuskens J. van Os J. De Hert M. MTHFR and risk of metabolic syndrome in patients with schizophrenia Schizophr. Res. 2010 121 193 198 10.1016/j.schres.2010.05.030 20547447
248. Herken H. Erdal M. Aydin N. Sengul C. Karadag F. Barlas O. Akin F. The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia DNA Cell. Biol. 2009 28 515 519 10.1089/dna.2009.0893 19622037
249. Muller D.J. Klempan T.A. De Luca V. Sicard T. Volavka J. Czobor P. Sheitman B.B. Lindenmayer J.P. Citrome L. McEvoy J.P. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia Neurosci. Lett. 2005 379 81 89 10.1016/j.neulet.2004.12.037 15823421
250. Basile V.S. Masellis M. McIntyre R.S. Meltzer H.Y. Lieberman J.A. Kennedy J.L. Genetic dissection of atypical antipsychotic-induced weight gain: Novel preliminary data on the pharmacogenetic puzzle J. Clin. Psychiatry 2001 62 5 66
251. Wang Y.C. Bai Y.M. Chen J.Y. Lin C.C. Lai I.C. Liou Y.J. Genetic association between TNF-alpha −308 G>A polymorphism and longitudinal weight change during clozapine treatment Hum. Psychopharmacol. 2010 25 303 309 10.1002/hup.1122 20521320
252. Amar A. Segman R.H. Shtrussberg S. Sherman L. Safirman C. Lerer B. Brautbar C. An association between clozapine-induced agranulocytosis in schizophrenics and HLA-DQB1*0201 Int. J. Neuropsychopharmacol. 1998 1 41 44 10.1017/S1461145798001023 11281944
253. Valevski A. Klein T. Gazit E. Meged S. Stein D. Elizur A. Narinsky E.R. Kutzuk D. Weizman A. HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients Eur. J. Immunogenet. 1998 25 11 13 10.1046/j.1365-2370.1998.00091.x 9587740
254. Dettling M. Schaub R.T. Mueller-Oerlinghausen B. Roots I. Cascorbi I. Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry Pharmacogenetics 2001 11 135 141 10.1097/00008571-200103000-00004 11266078
255. Saito T. Ikeda M. Mushiroda T. Ozeki T. Kondo K. Shimasaki A. Kawase K. Hashimoto S. Yamamori H. Yasuda Y. Pharmacogenomic Study of Clozapine-Induced Agranulocytosis/Granulocytopenia in a Japanese Population Biol. Psychiatry 2016 80 636 642 10.1016/j.biopsych.2015.12.006 26876947
256. Ostrousky O. Meged S. Loewenthal R. Valevski A. Weizman A. Carp H. Gazit E. NQO2 gene is associated with clozapine-induced agranulocytosis Tissue Antigens 2003 62 483 491 10.1046/j.1399-0039.2003.00133.x 14617031
257. Mosyagin I. Dettling M. Roots I. Mueller-Oerlinghausen B. Cascorbi I. Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis J. Clin. Psychopharmacol. 2004 24 613 617 10.1097/01.jcp.0000144891.52858.a6 15538122
258. Dettling M. Sachse C. Muller-Oerlinghausen B. Roots I. Brockmoller J. Rolfs A. Cascorbi I. Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: No association with myeloperoxidase and cytochrome P4502D6 Pharmacopsychiatry 2000 33 218 220 10.1055/s-2000-8359 11147929
259. Turbay D. Lieberman J. Alper C.A. Delgado J.C. Corzo D. Yunis J.J. Yunis E.J. Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups Blood 1997 89 4167 4174 10.1182/blood.V89.11.4167 9166860
260. Musil R. Spellmann I. Pharmacogenetics and cognitive symptoms in schizophrenia patients treated with antipsychotics Pharmacogenomics 2018 19 927 930 10.2217/pgs-2018-0083 30028229
261. Aberg K. Adkins D.E. Bukszar J. Webb B.T. Caroff S.N. Miller D.D. Sebat J. Stroup S. Fanous A.H. Vladimirov V.I. Genomewide association study of movement-related adverse antipsychotic effects Biol. Psychiatry. 2010 67 279 282 10.1016/j.biopsych.2009.08.036 19875103
262. Adkins D.E. Aberg K. McClay J.L. Bukszár J. Zhao Z. Jia P. Stroup T.S. Perkins D. McEvoy J.P. Lieberman J.A. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs Mol. Psychiatry 2011 16 321 332 10.1038/mp.2010.14 20195266
263. Alkelai A. Greenbaum L. Rigbi A. Kanyas K. Lerer B. Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients Psychopharmacology 2009 206 491 499 10.1007/s00213-009-1627-z 19680635
264. Hermes E. Nasrallah H. Davis V. Meyer J. McEvoy J. Goff D. Davis S. Stroup T.S. Swartz M. Lieberman J. The association between weight change and symptom reduction in the CATIE schizophrenia trial Schizophr. Res. 2011 128 166 170 10.1016/j.schres.2011.01.022 21334853
265. McClay J.L. Adkins D.E. Aberg K. Bukszar J. Khachane A.N. Keefe R.S. Perkins D.O. McEvoy J.P. Stroup T.S. Vann R.E. Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia Neuropsychopharmacology 2011 36 616 626 10.1038/npp.2010.193 21107309
266. Chagnon Y.C. Merette C. Bouchard R.H. Emond C. Roy M.A. Maziade M. A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses Mol. Psychiatry 2004 9 1067 1074 10.1038/sj.mp.4001537 15224101
267. Inada T. Koga M. Ishiguro H. Horiuchi Y. Syu A. Yoshio T. Takahashi N. Ozaki N. Arinami T. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia Pharm. Genom. 2008 18 317 323 10.1097/FPC.0b013e3282f70492
268. Zhang J.P. Robinson D. Yu J. Gallego J. Fleischhacker W.W. Kahn R.S. Crespo-Facorro B. Vazquez-Bourgon J. Kane J.M. Malhotra A.K. Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis Am. J. Psychiatry 2018 176 21 28 10.1176/appi.ajp.2018.17121363 30392411

